

Advancements and Challenges in the Application of Metal-Organic Framework (MOF) Nanocomposites for Tumor Diagnosis and Treatment

Yingze Hou^{1,2}, Can Zhu³, Ge Ban¹, Zhean Shen⁴, Yingbing Liang⁵, Kun Chen¹, Chenbo Wang¹, Heng Shi⁴

¹School of Intelligent Medical Engineering, Sanquan College of Xinxiang Medical University, Xinxiang, 453003, People's Republic of China; ²Clinical Medical College, Sanquan College of Xinxiang Medical University, Xinxiang, 453003, People's Republic of China; ³Department of Urology, The Second Clinical Medical College of Anhui Medical University, Hefei, 230032, People's Republic of China; ⁴Heart Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310000, People's Republic of China; ⁵Department of Chemistry and Biotechnology, Graduate School of Engineering Tottori University Koyama-Minami 4-101, Tottori, 680-8552, Japan

Correspondence: Ge Ban, School of Intelligent Medical Engineering, Sanquan College of Xinxiang Medical University, Xinxiang, 453003, People's Republic of China, Email bangel19@qq.com

Abstract: Nanoscale metal-organic frameworks (MOFs) offer high biocompatibility, nanomaterial permeability, substantial specific surface area, and well-defined pores. These properties make MOFs valuable in biomedical applications, including biological targeting and drug delivery. They also play a critical role in tumor diagnosis and treatment, including tumor cell targeting, identification, imaging, and therapeutic methods such as drug delivery, photothermal effects, photodynamic therapy, and immunogenic cell death. The diversity of MOFs with different metal centers, organics, and surface modifications underscores their multifaceted contributions to tumor research and treatment. This review is a summary of these roles and mechanisms. The final section of this review summarizes the current state of the field and discusses prospects that may bring MOFs closer to pharmaceutical applications.

Keywords: metal-organic frame, oncoterapy, photothermal effect, tumor immunity, drug delivery

Introduction

Nanomaterials demonstrate potential in diverse sectors, particularly within biomedicine, enabling interdisciplinary partnerships across materials science, physics, and chemistry. Integrating biological materials has substantially enhanced our comprehension of crucial life processes, presenting an innovative platform to investigate complex biological phenomena and characterize their corresponding molecular pathways.¹⁻⁵ However, the complex intricacies of biomedicine pose a challenge for single-component organic and inorganic materials in terms of their biological functionality while ensuring biocompatibility,⁶ as well as tackling concerns like cell or tissue toxicity.⁷⁻⁹

To tackle this issue, scientists have deliberately dispersed nanoscale organic and inorganic components throughout a polymer matrix, granting the composite material unique physical, chemical, and biological characteristics. The seminal 1989 study by Hoskins and Robson signaled the beginning of solid porous polymer materials.¹³ Expanding on an innovative idea, Yaghi et al¹⁴ produced an organic-inorganic hybrid substance featuring several pores, using the organic ligand BTC, and the transition metal ion Co²⁺. This revolutionary product, known as an organic-metal structure, frequently incorporates metal ions or clusters that create a central metal core, alongside organic ligands. The structured pores and significant specific surface areas of these materials have gained considerable attention from the academic community. Researchers have, through the modulation of metal central nodes and associated organic ligands, yielded an array of MOFs with diverse structures and functions. This diversified class of MOFs includes but is not limited to UIO-

66-Ce,^{15,16} Isoreticular Metal-Organic Framework (IRMOF),^{17,18} Materials of Institut Lavoisier (MIL),^{19,20} Zeolitic imidazolate framework (ZIF),^{21,22} Coordination Pillared-Layer (CPL),^{23,24} and Porous Coordination Network (PCN).^{25,26} The versatility of these MOFs is underpinned by the rich interplay of their structures and compositions. MOFs have various functionalities conferred by their diverse structures and compositions. They are currently utilized in several domains including nonlinear optics,^{27,28} biochemical sensing,^{29,30} catalysis,^{31,32} biological targeting,^{33,34} and drug delivery.^{35–37} Particularly, MOFs have proven to be highly significant in the field of targeted drug delivery. The considerable benefits of their elevated specific surface area permit the entrapment of diverse anti-tumor and antibacterial agents. Additionally, methods of modifying the surface and other approaches bolster the biocompatibility and precision of the delivery system toward the targeted site, thus tempering possible damage to regular tissue cells.^{38,39} The nanoscale dimensions of MOF materials enable them to bolster tissue penetration in tumor environments and augment drug bioavailability. As a result, they address the limitations associated with natural drug compounds, which are characterized by limited bioavailability and tissue penetration.⁴⁰ The use of nano-MOF materials in drug delivery, particularly in targeted therapies, has become a significant area of research. Researchers are constantly synthesizing and using a wide range of organic ligands, including multidentate ligands,^{41,42} phenolic ligands,^{43,44} and phosphorylated ligands,^{45,46} by dispersing them within the appropriate matrices to produce nano-MOF materials^{47–54} (Figure 1).

Amid the rapid evolution of the global economy and the accelerating pace of daily life, the incidence and mortality of chronic diseases, particularly tumors, have risen relentlessly. Tumors have now taken over the mantle of the second most common disease category, behind cardiovascular diseases. In the early stages of these diseases, clinical manifestations are often imperceptible, facilitating their insidious progression from the primary site to the adjacent tissue environment. This progression is associated with a trajectory of heterogeneous evolution⁵⁵ and the establishment of an immunosuppressive tumor microenvironment,⁵⁶ thereby enhancing the malignancy of the neoplasm. In many cases, the tumor has spread to distant sites by the time overt symptoms appear, posing an existential threat to the individual.

As a result, researchers from a variety of scientific disciplines have embarked on a proactive quest to address the global conundrum posed by tumors. This collective endeavor hinges on two main dimensions: early detection of malignant tumors and precise, late-stage therapeutic intervention. MOF materials, with their aptitude for biological targeting, high biocompatibility, and skillful surface functionalization, have emerged as an outstanding modality in the fight against malignant tumors. This includes their prominent role in the early diagnosis of malignant tumors using biological imaging and fluorescence-based methods.

Subsequently, nano-MOF materials have gradually entered the field of tumor therapeutics, primarily through their key contribution to drug delivery systems. However, the adoption of simplistic approaches to anti-tumor drug delivery has led to multi-drug resistance, exacerbated by the evolutionary heterogeneity of tumor cells,⁵⁷ thereby diluting the therapeutic efficacy of drug delivery. To solve this challenge, researchers synthesized a variety of nanocomposites based on MOF materials, in which different metal centers and organic ligands were discovered, and more convenient and efficient MOF synthesis methods were developed. These innovations in methods also provide a research basis for studying the biological activity of MOFs in the future. For example, more and more researchers have modified the surface of MOFs in the synthesis process to improve the sensitivity and specificity of MOFs in tumor diagnosis and treatment in combination with different tumor-targeting or treatment mechanisms. These multifaceted composites encompass various therapeutic modalities, including photodynamic therapy,⁵⁸ photothermal effects⁵⁹ and immunogenic cell death within the scope of tumor treatment.^{60–62} Such multi-dimensional interventions have the potential to improve prognosis and increase survival for affected individuals.

Given this, this review attempts to summarize the synthesis of MOFs, early diagnosis of tumors, targeted therapy, and intervention. To the best of our knowledge, existing scholarship, while embracing MOF materials within the broader biomedical spectrum, has often relegated the discourse on tumor diagnosis and treatment to a tangential annex within the biomedical ambit. Conspicuously absent from previous investigations is a systematic synthesis of early tumor diagnostics and the puzzles associated with such diagnostic strategies. This review attempts to fill this gap by providing a holistic panorama of the relevant facets of the field.




Figure 1 Schematic diagram of the application of MOF materials in different fields. Adapted from Cao, Y., Fu, M., Fan, S., Gao, C., Ma, Z., & Hou, D. Hydrophobic MOF/PDMS-Based QCM Sensors for VOCs Identification and Quantitative Detection in High-Humidity Environments. *ACS Appl Mat Inter*. 2024;16(6), 7721–7731. Copyright © 2024 American Chemical Society. Pardo, A., Gómez-Florit, M., Barbosa, S., Taboada, P., Domingues, R. M. A., & Gomes, M. E. (2021). Magnetic Nanocomposite Hydrogels for Tissue Engineering: Design Concepts and Remote Actuation Strategies to Control Cell Fate. *ACS nano*, 15(1), 175–209. Copyright © 2021 American Chemical Society. Andrés, M. A., Vijayap, M. T., Surya, S. G., Shekhah, O., Salama, K. N., Serre, C., Eddaoudi, M., Roubeau, O., & Gascón, I. (2020). Methanol and Humidity Capacitive Sensors Based on Thin Films of MOF Nanoparticles. *ACS Appl Mater Interfaces*, 12(3), 4155–4162. Copyright © 2020 American Chemical Society. Wang, P., Li, X., Zhang, P., Zhang, X., Shen, Y., Zheng, B., Wu, J., Li, S., Fu, Y., Zhang, W., & Huo, F. (2020). Transitional MOFs: Exposing Metal Sites with Porosity for Enhancing Catalytic Reaction Performance. *ACS Appl Mater Interfaces*, 12(21), 23968–23975. Copyright © 2020 American Chemical Society. Dong, J., Pan, Y., Yang, K., et al. Enhanced biological imaging via aggregation-induced emission active porous organic cages. *ACS nano*. 2022;16(2):2355–2368. Copyright © 2022 American Chemical Society. Wang, J.W., Chen, Q.W., Luo, G.F., et al. A self-driven bioreactor based on bacterium-metal-organic framework biohybrids for boosting chemotherapy via cyclic lactate catabolism. *ACS nano*. 2021;15(11):17870–17884. Copyright © 2021 American Chemical Society. Li, R., Chen, T., Pan, X. Metal-organic-framework-based materials for antimicrobial applications. *ACS Nano*. 2021;15(3):3808–3848. Copyright © 2021 American Chemical Society.^{47–54}

Synthesis of Metal-Organic Framework Materials

The synthesis of MOFs encompasses various methods, each hailing from diverse scientific disciplines. Remarkably, identical MOFs can be produced through differing techniques, influencing their physical and chemical attributes, thus impacting their biomedical utility. This section provides a concise overview of common synthesis methods.

One-Pot Synthesis of the MOFs

The one-pot synthesis method usually dissolves the reaction precursors in the solvent and carries out the related synthesis reaction under stirring. Liu et al⁶³ used ZrCl_4 and H4btcc to synthesize basic MOFs (UiO-66-(COOH)_2) in the system of acetic acid as solvent. $\text{CuNCs@Tb@UiO-66-(COOH)}_2$ was synthesized on basic MOFs by a one-pot method to detect Cu^{2+} content in water samples, providing an effective platform for the detection of heavy metal ions. Qing Li et al⁶⁴ synthesized ZIF-8 using $\text{Zn(NO}_3)_2 \cdot 6\text{H}_2\text{O}$ and 2-MIM in a one-pot method, and in the same method synthesized GOD @ Cu-ZIF-8 in $\text{Zn(NO}_3)_2 \cdot 6\text{H}_2\text{O}$ and $\text{Cu(NO}_3)_2 \cdot 4\text{H}_2\text{O}$ systems. These composite MOFs can break the tumor immunosuppressive microenvironment, stimulate covert antigen exposure, and in turn mediate the tumoricidal effect of CD8-positive T lymphocytes.

The main advantages of one-pot synthesis of MOFs are simple operation, low cost, and low requirements for experimental equipment. And the yield is also relatively large. Reagents can be continued during the reaction, ensuring the normal occurrence of reactions and the safety of the reaction system. However, the limitations of this method are also more obvious. Low purity of the synthesized MOFs, tend to contain more magazines. Therefore, if high-precision synthetic MOFs are needed, MOFs are generally not selected. Meanwhile, the remaining material on the MOFs may disturb the downstream experimental validation. Therefore, require a more careful determination of the characterization of the MOFs. To ensure the normal conduct of the downstream experiments for the.

Synthesis of MOFs by Hydrothermal Method

Hydrothermal method for the synthesis of MOFs is that the reaction mixture is in a relatively closed system using pressure or heat in a related synthesis. By mixing the reactants in an autoclave, the MOF nanomaterials were synthesized at a certain temperature. The MIL-53 (Al) @ AC material was synthesized by hydrothermal method, to improve the thermal stability and chemical stability of the composite system, and finally improve the performance of the MIL-53 material. The results of FESEM, EDS, TEM, and XPS show that the composite MOF system has good porosity and drug-loading capacity, and has certain adsorption effects on most cephalosporin antibiotics¹⁰ (Figure 2). Huanxuan Li et al⁶⁵ using $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$, $\text{Cu(NO}_3)_2 \cdot 3\text{H}_2\text{O}$, and DHTA dissolved in a mixed solution of DMF and ethanol. And transferred the resulting mixture to a Teflon-lined stainless steel autoclave for synthetic FeCu-MOF. The bimetal MOF material can more effectively remove water from methylene blue waste than the monumental MOF material et al⁶⁶ mixed $\text{Zn(NO}_3)_2$ and H2BDC in DMF. MOF-5 by hydrothermal synthesis, and compared with the one-pot synthesis of MOF-5, the results




Figure 2 MIL-53 (Al) MOF schematic diagram of the manufacturing process. Reprinted with permission from Imanipoor J, Mohammadi M. Porous aluminum-based metal-organic framework-aminoclay nanocomposite: sustainable synthesis and ultrahigh sorption of cephalosporin antibiotics. *Langmuir*. 2022;38(18):5900–5914. Copyright 2022 American Chemical Society.¹⁰

show that hydrothermal synthesis of crystallinity is better than the one-pot synthesis, this is mainly because compared with the one-pot method, the hydrothermal method requires the reaction system under a certain high pressure, high-pressure reaction conditions are conducive to the solubility of the precursor material in the solvent to promote the occurrence of the reaction. Hydrothermal synthesis of MOFs has good thermal stability and crystallinity, at the same time the specific surface area of MOFs is higher than the pot synthesis of MOFs, making the biological application of the material and drug loading capacity better than other reaction methods of MOFs, but hydrothermal synthesis also has more expensive, poor controllability disadvantages, at the same time, unlike ideal, in the reality of artificial high-pressure system pressure value often change in the reaction process of tightening, and this uncertain pressure conditions may affect the performance of the product.⁶⁷

Electrochemical Synthesis of MOFs

Electrochemical synthesis refers to the method of constructing MOF films on the matrix by electrooxidation or electro-reduction. Zhaowei Sun⁶⁸ synthesized Cu-MOF on the matrix surface by electrochemical deposition. Then, the modified electrode was immersed in HAuCl₄ solution and AuNP reduction on the Cu-MOF surface at 0.5V, and a composite membrane of Au NPs / MOF was formed on the electrode. Ameloot⁶⁹ depends on the metal ions produced by the anode metal plate in the reaction, and metal ions on the matrix by electrochemical synthesis Cu-MOF, while the reaction conditions control variable study found that when the voltage in the range of 2.5V to 25V, the metal ion concentration in the system will gradually increase, and the higher concentration of the crystal formed on the matrix will be smaller, and if water is added in the reaction system, will hinder the formation of MOF, make the larger crystals on the matrix.

Method of electrochemical synthesis method is the main advantage of the simple operation process, fast reaction speed, and can adjust the reaction system voltage, and the concentration of metal ions to adjust the thickness of MOFs, but at the same time because the method depends on the electrochemical reaction, so can only build on conductive substrate MOF film, this disadvantage limits the wide application of electrochemical synthesis method.⁷⁰

Application of NMOFs in Tumor Diagnosis

The imperative for accurate diagnostics of tumors underpins the treatment and monitoring strategies for oncological conditions. The quest for methods that are reliable, sensitive, rapid, and efficient for the detection of cancer biomarkers or live neoplastic cells cannot be overstated. Despite the utility of conventional imaging modalities, such as X-ray, computed tomography (CT),⁷¹ magnetic resonance imaging (MRI),⁷² positron emission tomography (PET),⁷³ PET-CT,⁷⁴ and photoacoustic imaging (PAI),⁷⁵ there remains a concerted effort to enhance these techniques. Innovations such as plasma resonance,⁷⁶ gel electrophoresis,⁷⁷ colorimetric assays,⁷⁸ and fluorescence detection⁷⁹ have been developed to discern tumorous tissues that manifest anomalous bioactive substance expression. While traditional methods offer direct macroscopic observation of tissues, these novel approaches aim to detect tumor-specific molecular expressions. However, each of these methodologies comes with its own set of constraints, which has propelled a substantial body of research towards the refinement of detection techniques. Within this research milieu, nanoporous metal-organic frameworks (NMOFs) have emerged as a material of significant promise in tumor diagnostic applications, owing to their multifaceted advantages. Subsequent sections will delineate the role of NMOFs in tumor diagnostics, addressing their utility in bioimaging.^{80,81} In the field of bioimaging, NMOFs play more of a developer role, with more powerful performance and targeting ability than conventional developers, or NMOFs with their own luminescence ability are directly involved in bioimaging. These development agents often enter the body through tail vein injection and enrich in the site of malignant tumor through corresponding targeting effects. These mechanisms are often related to the acidic microenvironment of tumor cells and the enrichment effect of tumor vascular space, and targeted diagnosis of malignant tumor combined with corresponding imaging methods.

Application of MOF Materials in Magnetic Resonance Imaging of Malignant Tumors

In the preceding decades, magnetic resonance imaging (MRI) has ascended to an indispensable role in clinical diagnostics, leveraging the fundamental principles of nuclear magnetic resonance.⁸² MRI's non-invasive nature, coupled with its sub-millimeter spatial resolution, enables detailed anatomical visualizations and functional assessments without

compromising tissue integrity. The technique's superior tissue contrast and penetration depth render it particularly advantageous for tumor detection and treatment monitoring.⁸³

The generation of MRI signals hinges on the nuclear magnetic resonance (NMR) signals of water protons within the tissue. Yet, the inherent signal contrast between pathologic and healthy tissues often falls short of lesion identification. Herein lies the utility of contrast agents, designed to modulate the relaxation times (T1 and T2) of water molecules in afflicted tissues, thus amplifying the delineation between normal and diseased states.⁸³ T1 is the longitudinal relaxation time and T2 is the transverse relaxation time. MRI analyzes the data by accepting the signal of relaxation and reveals a picture of the impact.⁸⁴ Due to the inherently low resolution of MRI, better imaging clarity often requires a large dose of developer. Optimal MRI contrast agents typically embody paramagnetic or superparamagnetic properties, furnished by elements such as gadolinium (Gd), iron (Fe), and manganese (Mn). For enhancing T1-weighted images, paramagnetic metals like Gd and Mn are preferred, whereas superparamagnetic Fe is sought for T2-weighted enhancements. Consequently, NMOFs imbued with these metals present as prime candidates for constructing MRI contrast agents. Pioneering this avenue, Lin et al in 2006 identified a Gd-based MOF exhibiting a longitudinal relaxation rate surpassing that of contemporaneous commercial T1 agents, marking a significant stride in MRI enhancement.⁸⁵ Subsequent research proliferated, particularly focusing on Gd-based MOFs. For instance, Yin et al synthesized a novel Gd-Ru complex, which outperformed the commercial agent Gd-DTPA in MRI contrast efficiency.⁸⁶ However, the cytotoxicity associated with in vivo Gd³⁺ release necessitated alternative strategies, prompting a shift towards Mn-based MOFs. In 2008, Lin et al harnessed reverse-phase microemulsion techniques to produce manganese-containing NMOFs, achieving moderate T1 relaxation with controllable morphologies.⁸⁷ Despite the superior imaging capabilities of Gd³⁺, MOFs as carriers for Mn²⁺ offered a platform for both in vivo and in vitro imaging applications. Evaluations of Mn²⁺-based MOFs through MTT assays affirmed their biocompatibility; even at elevated concentrations, these MOFs exhibited negligible cytotoxicity in various cell lines over 24 to 48 hours.⁸⁸ Recently, Chen et al advanced this domain by developing Mn²⁺ haemoglobin-based MOFs, significantly enhancing both MRI imaging and therapeutic outcomes in tumor applications.⁸⁹ So far clinically approved MRI contrast agents (CAs) have not been investigated systematically for the visualization of loading and release from MOF NPs. Konstantin Böll studied the loading and release of six clinically recognised CAs from MOF MIL-100 (Fe) in a clinical MRI environment. Standard procedures from sample preparation to MRI methods were developed for this purpose. The results were reproduced and validated by inductively coupled plasma atomic emission spectrometry (ICP-AES) and thiocyanate testing. The macrocyclic CA gadoteric acid glucosamine was identified as the best candidate CA for labelling MIL-100 (iron).

Application of MOF Materials in Computed Tomography of Malignant Tumors

Computed tomography (CT) emerges as a non-invasive radiological technique that affords three-dimensional visualization of internal structures, distinguished by its high spatial and temporal resolution.⁸⁹ The operational principle of CT imaging resides in the differential attenuation of X-rays, which is augmented by contrast agents comprised of elements with high atomic numbers, yielding pronounced X-ray absorption capabilities; this group includes iodine, gold, barium, bismuth, and gadolinium. The challenge, however, Challenges are relatively homogeneous attenuation values for various tissues, high side effects and high cost of contrast media.⁹⁰ Currently, the contrast agents used in CT clinics are mainly based on elemental iodine preparations, which are often toxic or costly.⁹¹

To ameliorate this limitation, contrast agents harboring high atomic number elements, known for their potent X-ray attenuation, are employed to enhance the visualization of target tissues against adjacent structures.⁹² MOFs that incorporate high Z-number metal cluster nodes, such as hafnium (Z=72) and zirconium (Z=40), have been engineered. These MOFs exploit the photoelectric effect, where Hf(IV) and Zr(IV) cations serve as efficient antennae, absorbing X-ray photons and subsequently emitting swift electrons.⁹³ Investigative studies by Lin et al assessed two NMOFs, Zr-uoio and Hf-uoio, for their utility as CT contrast agents, noting substantial metal content (37 wt% Zr and 57 wt% Hf) and consequent contrast enhancement.⁹³ Furthermore, the element gold (Au), with its eminent atomic number and superior X-ray attenuation coefficient, emerges as an exemplary candidate for CT contrast agents. Boyes et al innovated by amalgamating GdMOF nanoparticles with gold nanoparticles (AuNPs), crafting highly stable hybrid composites, with the




Figure 3 The synthetic strategy for fabricating hybrid GdMOF-PAA-Au nanostructures involves a sequential multi-step process: (a) the initial deposition of poly(acrylic acid) (PAA) onto the surface of gadolinium metal-organic framework (GdMOF) nanostructures, (b) the subsequent adsorption of gold (Au) ions onto the PAA-functionalized GdMOF nanostructures, and (c) the reduction of the Au ions, culminating in the formation of gold nanoparticles (AuNPs) firmly entrapped within the PAA matrix on the nanostructure's surface. (d) A schematic delineation of the hybrid nanostructure is presented, where the GdMOF core is depicted in blue, the entangled PAA chains in blue, and the incorporated AuNPs are illustrated in gold, demonstrating the complex's structural composition and the spatial distribution of its constituents. Reprinted with permission from Tian C, Zhu L, Lin F, Boyes SG. Poly(acrylic acid) Bridged gadolinium metal-organic framework-gold nanoparticle composites as contrast agents for computed tomography and magnetic resonance bimodal imaging. *ACS Appl Mater Inter.* 2015;7(32):17765–17775. Copyright 2015 American Chemical Society.¹¹

synthesis intermediated by polyacrylic acid, as depicted in Figure 3¹¹ When chelated with MOFs, gold demonstrates exceptional contrast enhancement, markedly outperforming conventional agents in efficacy.

In the advancement of computed tomography (CT) contrast agents, researchers have extended their investigations beyond the traditional high atomic number elements, exploring the potential of MOFs with integrated contrast-enhancing moieties. Xie et al developed a novel class of MOF nanocrystals, designated as UiO-PDT, which encapsulate iodine-boron-dipyrromethene (BODIPY) within their lattice. Comprehensive studies were undertaken to evaluate the biosafety and contrast efficacy of these nanocrystals, revealing no significant acute or subacute toxicity at injection doses up to 100 mg kg^{−1}.⁹⁴ In vivo CT imaging demonstrated the preferential accumulation of UiO-PDT nanocrystals within the tumor sites of hepatoma-bearing rats, offering distinct delineation from surrounding connective tissues and organs. Concurrently, Farha et al pioneered the synthesis of a bismuth-based MOF, termed bismuth-NU-901 (Bi-NU-901), employing a hot solvent fabrication technique. Remarkably, in vitro assessments of Bi-NU-901 disclosed a sevenfold enhancement in contrast intensity relative to isorecticular zirconium MOFs, and a striking fourteenfold increase in contrast ratio in comparison to commercially available CT contrast agents, underscoring the potential of this novel bismuth MOF in CT imaging applications.⁹⁵

In summary, most of the research on CT contrast agents has been limited to improving contrast performance, and there is a lack of research on reagent biosafety and cost control.

Application of MOF Materials in PET of Malignant Tumors

Positron emission tomography (PET) represents a sophisticated functional imaging modality that utilizes metabolically active substances labeled with ephemeral radionuclides for diagnostic imaging.⁹⁶ PET is distinguished by its superior detection sensitivity and deep signal penetration when compared to other imaging techniques. Nanoscale MOFs embedded with positron-emitting radioisotopes emerge as optimal agents for PET applications.^{74,97}

The work of Hong et al introduced an nMOF complexed with the positron-emitting isotope zirconium-89 (⁸⁹Zr), specifically targeting MDA-MB-231 cells (triple-negative breast cancer cells, overexpressing nucleolin). Their construct, ⁸⁹Zr-UiO-66Py PGA-PEG-F3, exhibited robust radiochemical stability and retained material integrity within various biological media. PET scans facilitated the in vivo mapping of ⁸⁹Zr-UiO-66Py PGA-PEG-F3's biodistribution and enabled the detection of 8.2±0.3% of the total injected dose per gram of tumor tissue at 2 hours post intravenous administration. Complementing this, Liu et al reported on a different MOF system for PET, employing the radioisotope copper-64 (⁶⁴Cu) and the framework ZIF-8, noting an enhancement in biosafety profiles. Their findings also highlighted




Figure 4 ^{89}Zr -Uio-66 for the treatment of tumors and PET imaging. Reprinted with permission from Duan D, Liu H, Xu M, et al. Size-controlled synthesis of drug-loaded zeolitic imidazolate framework in aqueous solution and size effect on their cancer theranostics in vivo. *ACS Appl Mater Inter*. 2018;10(49):42165–42174. Copyright © 2018 American Chemical Society.¹²

a correlation between nanoparticle size and diagnostic or therapeutic efficacy; smaller nanoparticles yielded improved imaging resolution, whereas larger counterparts were more effective in tumor treatment¹² (Figure 4).

Application of MOF Materials in PAI of Malignant Tumors

Photoacoustic imaging (PAI) represents an emergent, non-ionizing biomedical imaging modality, capitalizing on the photoacoustic effect inherent in light absorbers.⁹⁸ The technique synergistically marries the superior selectivity of optical imaging with the extensive penetration capabilities of ultrasound, thereby transcending the limitations imposed by light scattering and extending the boundaries of high-resolution optical imaging.⁹⁸

Contrast agents commonly used in PAI include: organic dye molecular contrast agents, noble metal contrast agents, carbon nanomaterial contrast agents, and metal oxides. The recent deployment of NMOFs as PAI contrast agents has been propelled by their desirable characteristics: expansive porosity, adjustable pore dimensions, copious metal coordination sites, and substantial capacity for guest molecule accommodation. These traits facilitate their engineering as dual-function agents, adept in both PAI contrast and therapeutic delivery. Initially, scientists tried using common biological dyes in combination with MOFs, and achieved superior shared properties by exploiting the high loading properties of MOFs. Illustratively, Chen et al crafted multifunctional MOF nanoparticles employing MIL-100 (Fe) for PAI-directed concurrent chemo- and photothermal therapy.⁹⁹ Their methodology encompassed the use of polydopamine (PDA)-coated curcumin iron-based MOF to enhance colloidal robustness and biocompatibility, thereby bolstering PAI and photothermal conversion efficiencies. Further, the nanocomposites were modified with hyaluronic acid (HA)-linked PDA to selectively engage CD44-overexpressing tumor cells, culminating in an integrated approach for PAI facilitation and photothermal treatment. Complementarily, Yuan et al constructed a novel metal-organic nanotherapeutic, Cu-THQNPs, by coordinating tetrahydroxyanthraquinone (THQ), an organic dye, with Cu^{2+} ions, which serves as a dual-mode agent for PAI-guided photothermal/chemotherapy within the NIR-II window (1000 to 1350 nm).¹⁰⁰ This material exhibited exemplary photothermal attributes and PAI efficacy in the NIR-II regime. Furthering this innovation, He et al engineered a nanoscale porphyrin-palladium MOF (Pd-MOF), interspersed with finely distributed Pd atoms, capable of transporting potent reducing agents such as hydrogen, making it suitable for PAI-steered hydrothermal tumor therapy. The Pd-MOF demonstrated formidable efficacy in tumor-targeted hydrogen delivery, endorsing its utility in therapeutic applications.¹⁰¹

Application of MOF Materials in Fluorescence Imaging of Malignant Tumors

Fluorescence bioimaging stands as a distinguished technique, predicated on the excitation of fluorophores through photon absorption at discrete wavelengths, followed by photon emission at longer, higher-energy wavelengths.¹⁰² However, the

method grapples with challenges in quantifying fluorescence intensity within biological entities, encumbered by auto-fluorescence, tissue signal attenuation, and inadequate light penetration in superficial tissues. Such challenges have spurred intense research into fluorescent materials to bolster optical imaging, particularly for deep tissue and intracellular applications.¹⁰³

Advancements in this domain have been notably marked by the advent of luminescent MOFs, lauded over the past two decades for attributes including substantial payload capacities, tunable surface chemistries for enhanced pharmacokinetics, and variable sizes and structures.¹⁰⁴ Research has yielded a plethora of MOF constructs with luminescent capabilities, ranging from those incorporating fluorescent dyes or drugs to those intrinsically luminescent. Lanthanide-incorporated MOFs have elicited considerable interest due to their precise and stable emission, pronounced Stokes shifts, protracted fluorescence lifetimes, and the capacity for improved spectral and temporal differentiation from background auto-fluorescence.¹⁰⁵ Indocyanine green (ICG) is the only organic fluorophore in the near-infrared region (NIR) approved by FDA for medical application. However, the poor water solubility, insufficient fluorescence imaging specificity and sensitivity to tumor limit its clinical application in cancer diagnosis. A novel stratagem reported by Wuttke et al involves the encapsulation of fluorescein within lipid-coated MOFs,¹⁰⁶ producing MOF@lipid nanoparticles that harmonize the virtues of liposomes with porous entities, safeguarding dye molecules within MOF cavities while mitigating premature release and enhancing colloidal stability. In vivo trials have shown these fluorescein-laden nanoparticles to concentrate within T24 human bladder cancer cells, exhibiting potent emission profiles.

Furthermore, fluorescence imaging efficacy has been augmented through specialized tactics such as aggregation-induced emission and quenching. Liu et al engineered a biocompatible nanoscale zirconium porphyrin MOF (NPMOF) that leveraged high porphyrin loading for efficacious fluorescence imaging and therapy guidance.¹⁰⁷ In the burgeoning sphere of biological imaging sensors, DNA-based intracellular systems have made significant headway. Gao et al introduced a groundbreaking photo-activated locomotion mechanism over gold nanoparticle surfaces, triggered by photolysis, which reduces the pre-activation requisites in vivo. The mechanism encompasses enveloping nanoparticles within a dissociable ZIF-8 MOF, facilitating the autonomous pinpointing of target DNA sequences. The experimental data underscore the composite nano-system's precision and specificity in microRNA-21 identification, heralding a versatile paradigm for fluorescence-based tumor cell sensing and imaging¹⁰⁸ (Figure 5).




Figure 5 A ZIF-8-based platform for self-driven tumor DNA imaging sensing schematic diagram of the manufacturing process. Reprinted with permission from Gao J-L, Liu Y-H, Zheng B, et al. Light-activated and self-driven autonomous DNA nanomachine enabling fluorescence imaging of MicroRNA in living cells with exceptional precision and efficiency. *ACS Appl Mater Inter.* 2021;13(27):31485–31494. Copyright 2021 American Chemical Society.¹⁰⁸

The integration of luminescent properties into MOFs has significantly expanded their utility in biomedical imaging, particularly through the inclusion of lanthanide-based MOFs, which are well-suited for fluorescence imaging modalities. Meng et al have exemplified this application by employing a lamellar europium MOF (EuMOF) to create a theranostic nano platform, facilitating simultaneous microwave thermo-chemotherapy and fluorescence imaging.¹⁰⁹ Their studies revealed that the EuMOF@ZIF/AP-PEG nanocomposite maintained robust fluorescence up to six hours post-in situ administration.

Furthermore, the biomedical field has recently embraced up-conversion luminescent nanoparticles (UCNPs), which possess the remarkable ability to transmute near-infrared (NIR) radiation into visible light. These nanoparticles enhance the repertoire of bio-probes by mitigating autofluorescence interference in optical imaging conducted in vivo and by reducing the risk of light-induced damage in cellular cultures and live subjects. The unique optical characteristics of UCNPs present them as a transformative element in the domain of optical imaging, aligning with the overarching goal of minimizing phototoxic effects while maximizing imaging clarity.^{110,111} nMOFs is no longer just a carrier for fluorescent dyes. However, It is crucial to note that local delivery and imaging confirmation of drug distribution within the tumor are still lacking in the case of MOFs nanomaterials.

Application of MOF Materials in Multi-Modal Imaging of Malignant Tumors

Contemporary imaging modalities, including fluorescence, magnetic resonance imaging (MRI), and computed tomography (CT), each present a unique set of advantages and inherent limitations. Fluorescence imaging boasts high sensitivity yet suffers from limited penetration depth. MRI offers exquisite three-dimensional soft tissue delineation, albeit with constrained planar resolution. CT excels in visualizing osseous structures and calcifications but exhibits reduced sensitivity to soft tissues.¹¹² The reliance on single-modality imaging techniques offers an incomplete diagnostic picture, significantly impeding the efficacy of oncological diagnostics. Nonetheless, the convergence of these disparate imaging technologies can surmount individual limitations, yielding a composite diagnostic vista replete with detailed and reliable pathological insights—critical for the precise diagnosis and treatment of cancer. Within this multidisciplinary framework, nMOFs provide a versatile platform conducive to the integration of multiple imaging modalities.¹¹³ For instance, Tang et al synthesized core-shell nanocomposites that harness upconversion luminescence (UCL) and MRI by encapsulating MOFs (MIL-101 (Fe)) around UCNPs.¹¹⁴ These composites have demonstrated effective tumor-site enrichment and commendable UCL/MRI performance 24 hours following intravenous administration.

Further, Bai et al crafted novel core-shell PB@MIL-100 (Fe) bimetallic organic framework (d-MOF) nanoparticles, which feature an inner PB MOF core and an outer MIL-100(Fe) MOF shell, endowing them with efficacy as contrast agents for T1/T2 bimodal MRI and fluorescence optical imaging (FOI). These nanoparticles are also responsive to acidic environments, facilitating the release of encapsulated artemisinin for enhanced tumor therapy.¹¹⁵

The evolution of imaging modalities has not halted at dual-modality; the advent of MOFs with high payload capacities has paved the way for tri-modal imaging platforms, offering superior capabilities. Chen et al developed a multifunctional nanoplatform employing hyaluronic acid (HA) and indocyanine green (ICG)-engineered MIL-100 (Fe) nanoparticles (MOF@HA@ICG NPs), which enable imaging across MR, PA, and FL modalities, effectively overcoming the challenges of limited penetration depth and sensitivity inherent to single-mode imaging.¹¹⁶ Wang et al, in their pursuit of comprehensive diagnostics and therapy, introduced an all-encompassing strategy for the synthesis of bimetallic-ligand MOFs, specifically Fe/TM-MOFs, incorporating Fe^{3+} and Tm^{3+} ions with 2-methylimidazole and metabenzonic acid ligands. These MOFs exhibit a potent Fenton catalytic effect by reacting with H_2O_2 to generate free radicals for tumor treatment, while simultaneously enabling fluorescence imaging, photothermal imaging, and MRI.¹¹⁷

MOFs are garnering considerable interest in the realm of biomedical imaging, standing out as potential multi-functional agents by their synthetic adaptability and dual capacity for imaging and therapeutic delivery. The imaging functionalities of MOFs may be inherent to their structure or introduced via post-synthetic incorporation of guest molecules within their pores or on their surfaces. Additionally, the structural pliability of MOFs permits facile hybridization with an array of other nanomaterials, enhancing their application scope. The intrinsic versatility of MOFs allows for the integration of diverse imaging modalities within a single particulate entity, thereby establishing a platform for multimodal imaging agents.

Multimodal Killing and Therapeutic Effects of MOFs on Tumor Cells

Malignant neoplasms present a formidable challenge in contemporary medicine, characterized by high incidence, poor prognostic outcomes, and a propensity for recurrence. Compounded by lifestyle factors and societal pressures, malignancies are increasingly affecting younger demographics, constituting a global health issue.^{118–120} Conventional treatments in clinical oncology—chemotherapy,¹²¹ radiotherapy,¹²² and surgical excision¹²³—each bear their own set of constraints. Chemotherapeutic approaches are often compromised by the emergence of drug-resistant cellular clones due to tumor heterogeneity, necessitating escalated drug concentrations that concurrently escalate cytotoxic risks, thus presenting a therapeutic conundrum.^{124–126} The utility of radiotherapy is circumscribed by its inexactitude, inefficiency, and substantial adverse effects.^{127,128} Surgical interventions, while standard, are frequently challenged by the invasive and metastatic nature of malignant cells, raising the risk of residual disease and subsequent recurrence.

In light of these limitations, there has been a pivot towards less invasive, non-toxic, and more manageable therapeutic modalities such as thermodynamic therapy, photodynamic therapy, and immunotherapy. Yet, these innovative approaches are not without their limitations. For instance, chemodynamic therapy is often stymied by an inability to generate sufficient hydrogen peroxide within the tumor microenvironment.¹²⁹ Photodynamic therapy's efficacy is limited by the instability of photosensitizers within tumor tissues and the requirement for higher oxygen levels, which is at odds with the hypoxia typical of tumor metabolic reprogramming.¹³⁰ Immunotherapy's potential is frequently undermined by an immunosuppressive milieu fostered by tumor-associated immune cells and the evasion of immune surveillance by tumor cells.^{128,129} Consequently, the scientific community remains engaged in the development of more efficacious treatment strategies to augment therapeutic outcomes in oncology^{131,132} (Figure 6).

The advancement of nanomaterial research has catalyzed the synthesis and implementation of novel material types in oncological therapy, mitigating some of the limitations inherent in traditional treatment modalities and offering innovative directions for clinical cancer management.^{133–135} MOFs, owing to their extensive specific surface area, permeability, and well-ordered porous structures, have emerged as a prominent class of materials in the realm of tumor-targeted therapy. The versatility of MOFs is demonstrated through a spectrum of applications, including but not limited to targeted drug delivery, integration with photodynamic therapy for the conveyance of photosensitizers, and leveraging photo-thermal effects to potentiate the immune response against neoplastic cells (Table 1).^{51,135–142}




Table 1 Summary of the Tumor-Killing Effects of Different MOF-Based Nanocarriers

Material	Synthetic Method	Applications	Therapeutic Agents	Refs.
Zr-MOF	Hydrothermal method	Chemical therapy	5-FU	[135]
DOX@H-PMOF@mem	A pot of method	Chemical therapy	DOX	[136]
(DOX and ICG) @H-PMOF@mem	A pot of method	Chemotherapy, photodynamic therapy, the photothermal effect of the three modes of synergistic therapy	DOX	[51]
CMT NPs	–	Photothermal therapy (an indirect boost to immunotherapy)	Polypeptide tuftsin	[137]
Mn-IR825@PDAPEG	A pot of method	Photothermal therapy	–	[138]
DOX-ZIF-8/CQD	–	Chemotherapy, photodynamic therapy, the photothermal effect of the three modes of synergistic therapy	DOX	[139]
Hf@H2DBP	Hydrothermal method	Photodynamic therapy	H2DBP	[140]
PCN-224	–	Photodynamic therapy	TCPP	[141]
ZIF-8@AuNCs@DOX	–	Chemotherapy with synergistic photodynamic therapy	AuNCs@DOX	[142]

MOFs Treat Tumors by Targeted Drug Loading

Xi-Yu Sun et al ingeniously crafted a functionalized MOF, UiO-67-CDC, employing zirconium tetrachloride and 9H-carbazole-2,7-dicarboxylic acid via hydrothermal synthesis. Subsequently, they modified UiO-67-CDC by substituting the Lewis base sites with two methyl groups, thereby engendering a positively charged framework, UiO-67-CDC-(CH₃)₂. This modified Zr-MOF exhibited a pronounced affinity for the chemotherapeutic agent 5-fluorouracil (5-FU), achieving an impressive drug loading rate of 56.5%. Simulating physiological conditions, the UiO-67-CDC-(CH₃)₂@5-FU complex showcased commendable stability and responsiveness in a liquid medium with a pH of 7.4, indicative of its potential for targeted drug delivery within the bloodstream.¹³⁶ At the same time, the targeting vector has good degradation ability in an acidic environment, which gives the composite system a good tumor targeting effect. As we all know, tumor cells undergo a large number of anaerobic glycolysis processes due to the Warburg effect, which will form a local lactic acid microenvironment around tumor tissues, so that UiO-67-CDC-(CH₃)₂@5-FU will release drugs in response to the change of Ph after entering tumor blood vessels from the blood circulation, and play a targeted role in tumor cells.

In a parallel study, Xin Sun et al synthesized ZIF-8 nanoparticles by solvating zinc nitrate hexahydrate and 2-methylimidazole in methanol, followed by centrifugation and surface modification with polyvinylpyrrolidone (PVP) in dimethylformamide. This precursor was then integrated with zirconium tetrachloride and tetrakis (4-carboxyphenyl) porphyrin to fabricate a hybrid porphyrin MOF (H-PMOF), onto which doxorubicin (DOX) was loaded to construct a tumor-targeted, controlled-release system. To extend the MOF complex's circulatory longevity, a biomimetic approach was employed, enrobing DOX@H-PMOF with a breast cancer cell membrane to yield the DOX@H-PMOF@mem complex, thereby enhancing biocompatibility and mediating immune evasion. Efficacy assessment through in vivo and in vitro studies confirmed that DOX-loaded MOF materials significantly augmented the bioavailability of the chemotherapeutic drug and impeded the onset of tumor chemoresistance, exhibiting potent anticancer activity. Moreover, the MOF composite's capacity to mitigate liver and lung metastases—common in breast cancer—was evaluated. While the standalone chemotherapeutic delivery system exhibited moderate efficacy against metastatic progression, the tri-modal targeted system (DOX and indocyanine green (ICG))@H-PMOF@mem, synergizing chemotherapy with photodynamic and photothermal therapies, demonstrated substantial inhibitory effects on the metastatic spread of breast cancer.⁵¹

Long-term basic research and clinical retrospective research show that the maximum role of MOFs drug carriers in the body's blood circulation is largely related to the structure, particle size and charge of the loaded drugs. For example, when the particle size is 20nm-200nm, it can effectively reduce the recognition, phagocytosis and presentation of foreign nanoparticles by immune cells of the body, thus improving the peripheral circulation time. At the same time,

nanoparticles carrying a small amount of negative charge will also effectively prolong the circulation time and improve the targeting effect on tumor cells. After a long-term meta-analysis, it is known that DOX,^{137–139} curcumin,¹⁴³ fluorouracil¹⁴⁰ and other drugs have the least systemic adverse effects, so MOFs loaded with these drugs can be used as potential clinical anti-tumor drugs, but it requires the joint efforts of long-term immunotoxicity, cell tissue toxicity and multi-center clinical research, and it is expected that in the future.

Targeted MOFs Combined with Photothermal Effects to Treat Tumors

Hongmi Zou et al synthesized carbonized magnetic nanoparticles (CM NPs) by subjecting Fe nanoparticles to high-temperature carbonization within a tube furnace under an argon atmosphere for five hours. The resultant CM NPs were subsequently treated with 30% hydrogen peroxide and functionalized with the peptide tuftsin to yield CMT NPs. The CMT NPs are carbonized from Mil-100 (Fe) at high temperatures and retain their original magnetism. On the one hand, the MOF system actively accumulates in tumor tissues by magnetism; on the other hand, tumor angiogenesis involves the signal transduction process of many cytokines, so it takes a long time. Therefore, many newly formed tiny capillaries in tumor tissues are not tight histologically, allowing particles with a particle size of 100nm–2mm to enter and passively accumulate in tumor tissues, which is called the EPR effect. Therefore, the compound system uses the dual targeting mechanism to target tumor cells and play the roles of photothermal effect and immunogenic death. Experimental validation revealed that these composite nanoparticles possess efficient photothermal conversion properties, with temperatures reaching up to 57.5°C upon 808 nm laser irradiation. Notably, the photothermal efficiency, quantified at 27.08%, displayed a strong dependence on the nanoparticle concentration and irradiation duration. While this efficiency trails that of gold-based composites, the tuftsin moiety within the CMT NPs facilitates the polarization of macrophages towards a pro-inflammatory M1 phenotype within the tumor microenvironment, augmenting the secretion of cytokines and the recruitment of T and B lymphocytes to the tumor site, thus enhancing the immunogenic assault on retinoblastoma cells.¹⁴⁴

In parallel, Yang et al constructed a self-assembled MOF using Mn^{2+} as the metallic core and PTAIR825 as the organic linker. The stability of this MOF under photothermal conditions was further enhanced by surface modification with polydopamine and polyethylene glycol, yielding Mn-IR825@PDAPEG nanoparticles. These self-assembled nanoparticles demonstrated potent photothermal conversion and tumor ablation capabilities when subjected to 808 nm laser irradiation.¹⁴⁵ Complementing these findings, Tian et al developed a multifaceted nanoparticle system by encapsulating graphene quantum dots (GQD) and the chemotherapeutic agent doxorubicin (DOX) within the ZIF-8 MOF matrix, creating DOX-ZIF-8/CQD nanoparticles. The composite leverages the exceptional photothermal properties and upconversion potential of GQDs, allowing for precise control over photothermal conversion via adjustments in near-infrared (NIR) intensity and exposure time. Additionally, the photothermal activity of the GQDs enhances the pH responsiveness of ZIF-8, concurrently facilitating the release of DOX.¹⁴⁵ This study corroborates the promising therapeutic potential of MOF-based platforms in realizing synergistic chemo-photothermal treatments for malignancies.^{141,147,148} Graphene quantum dots (QDs) have good biocompatibility and low tissue cytotoxicity, and a composite material system is constructed with MOFs, which can use its good drug loading activity to organically combine QDs,¹⁴⁹ MOF and photosensitizer to play a synergistic role in killing tumor cells. For example, in clinical practice, More and more doctors began to use natural photosensitizers such as indocyanine green for angiography,¹⁵⁰ fibrosis therapy¹⁵¹ and tumor photothermal therapy.¹⁴² However, this treatment strategy still has some limitations, such as poor biocompatibility and targeting ability, so we can choose to combine it with MOF, graphene quantum dots and other materials to build a targeted photothermal therapy system to cooperate with tumor killing.¹⁵¹

Targeted MOFs Combined with Photodynamic Therapy to Treat Tumors

Lu et al pioneered the synthesis of a nanoscale MOF utilizing a hydrothermal method with hafnium tetrachloride ($HfCl_4$) and a porphyrin derivative, H2DBP. This novel MOF serves as a dispersal platform for photosensitizers, effectively mitigating aggregation and self-quenching while enhancing the production of singlet oxygen species in the vicinity of tumor tissues. Such advancements bolster the efficacy of photodynamic therapy (PDT) in oncological applications. In vivo investigations revealed a notable reduction in tumor volume in half of the treated mice, with the remainder

achieving complete tumor eradication.¹⁵² The integration of PDT with MOF-based targeting platforms is thus recognized as a promising avenue in cancer therapy, drawing significant research interest. Current explorations extend beyond hafnium-based MOFs to other metal centers such as zirconium,¹⁵³ manganese,¹⁵⁴ and iron,¹⁵⁵ broadening the scope of MOF applications in PDT.

Park et al synthesized the spherical MOF material PCN-224 by coordinating Zr6 clusters with (4-carboxyphenyl) porphyrin (TCPP), featuring tunable sizes to enhance tumor permeability and uptake, thereby facilitating drug accumulation and tumor eradication.¹⁵⁶ Park also proposed surface modifications, such as the conjugation of targeting moieties like folic acid, which may potentiate the tumor-targeting and PDT effects of the system.^{157–159} The innovation of encapsulating photosensitizers within MOFs or employing surface modifications and core-shell structures has transcended the constraints of using solely porphyrin-based photosensitizers, fostering the development of intricate MOF complexes. For example, Zhang et al¹⁶⁰ introduced gold nanoclusters (AuNCs) as photosensitizers within a pH-responsive ZIF-8@AuNCs@DOX composite, where the acidic tumor microenvironment triggers the disintegration of ZIF-8, releasing AuNCs and DOX for combined PDT and chemotherapy. This targeting system mainly targets tumor cells by acid response. Because ZIF-8 has good degradation efficiency in an acidic environment, photosensitizer and chemotherapy drug DOX are released in tumor tissue after contacting the acidic microenvironment of tumor tissue for targeted tumor killing and treatment.

Furthering this multidisciplinary approach, Chen and collaborators synthesized Cu-TCPP (Al) and Pt nanoparticles using a hydrothermal method, yielding a surface-modified composite, (Cu-TCPP (Al)-Pt). This composite nanosystem, delivering NH₂-PEG-FA, targets tumor cells for cytotoxicity. The Cu^{II} active center within the system depletes glutathione levels in tumor cells, amplifying reactive oxygen species (ROS)-induced damage, while the Pt nanoparticles catalyze the conversion of hydrogen peroxide to oxygen. This dual action not only disrupts tumor cell glycolysis but also counters the reprogramming of immune cells caused by the hypoxic tumor microenvironment,




Figure 7 Schematic of (A) the fabrication process and (B) Cu-TCPP (Al) -Pt-FA stimulates the development of tumor immunity by depleting glutathione in cancer cells to enhance the effects of ROS and catalyzing O₂ production by Pt NPs to reduce the inhibitory effect of tumor-induced hypoxic microenvironment on immune cells. Reprinted with permission from Chen Z, Wu Y, Yao Z, et al. 2D Copper(II) metalated metal-organic framework nanocomplexes for dual-enhanced photodynamic therapy and amplified antitumor immunity. *ACS Appl Mater Inter.* 2022;14(39):44199–44210. Copyright 2022 American Chemical Society.¹⁶¹

enhancing the immune response and curtailing tumor cell immune evasion and epithelial-mesenchymal transition¹⁶¹ (Figure 7).

Conclusively, MOFs have become integral to the design of drug delivery systems, leveraging their structurally ordered porosity, extensive surface area, and permeability for effective drug loading. These characteristics facilitate the integration of MOFs with a spectrum of therapeutic modalities—including chemotherapy, photodynamic, and photothermal therapies construct targeted delivery systems aimed at malignancies, enabling multifaceted and multivalent attack strategies on tumor cells. However, empirical evidence indicates that MOF-based targeting systems, when used in isolation, may not ensure the complete eradication of tumors *in vivo*. Given the rapid proliferation capability of residual neoplastic cells, incomplete tumor removal can precipitate recurrence and augment patient suffering. Enhancing tumor ablation may therefore necessitate a multimodal cooperative targeting approach. As delineated in the synthesis of the tripartite treatment paradigms above, employing MOFs as a co-delivery platform for a dual-mode or even tri-mode amalgamation of chemotherapy, photodynamic, and photothermal therapies demonstrates superior efficacy in tumor cell destruction compared to monotherapy applications.^{162–164}

Conclusions

MOFs, a burgeoning class of porous nanomaterials, have captivated the scientific community with their varied composition, customizable architectures, expansive surface areas, porosity, and commendable biocompatibility. These attributes have rendered them exceedingly versatile for the conveyance of diverse functional entities—ranging from ions to proteins, enzymes, photosensitizers, chemotherapeutic agents, and targeted antigens.^{165–168} The strategic functionalization of MOF nanomaterials has been pivotal in enhancing their target specificity—active or passive—toward neoplastic tissues, thereby revolutionizing the targeted diagnostic and therapeutic paradigms for malignancies. Consequently, a proliferation of MOF-based intelligent nano-targeting platforms has emerged, addressing the difficult needs in global oncological diagnostics and therapeutics. Concurrently, innovations in clinical methodologies for malignant pathologies—encompassing photodynamic therapy, photothermal effects, and immunogenic cell death—have somewhat alleviated the onus on treatment regimes. In summary, MOF has demonstrated superior performance in tumor diagnostics, especially in bioimaging, due to its special structure. From fluorescence imaging, MRI, CT, etc., excellent performance MOF materials have appeared in various imaging modalities. There are many improvements to commercial visualizers, such as MOF-loaded visualizers or the use of metallic MOFs to meet the demand, all of which have demonstrated significant performance improvements. At the same time, many studies show that the combination of nano-metal core-shell constructed with metals, especially precious metals, and MOFs will effectively improve the photothermal effect and the efficiency of photodynamic therapy of MOFs, damage tumor cells more effectively to promote the immunogenic death of tumors and play a better role in tumor treatment. Moreover, the properties of the composite can be further improved effectively by changing the types, structures, and surface modification of the surface metal core-shell to achieve better therapeutic effects.^{2,4,169}

Outlook

Although through the joint research of many scientists from different fields, MOF materials have been proven to apply to many tumors and play a role in targeted diagnosis and treatment. However, the inherent limitations of these nascent monotherapies, coupled with the heterogeneity of tumor cell evolution,¹⁷⁰ metabolic reprogramming,¹⁷¹ and immunosuppressive microenvironments,¹⁷² preclude the complete eradication of tumor cells. To surmount these impediments, researchers have advocated employing MOFs as multifaceted platforms, synergizing with photodynamic and photothermal therapies to enhance malignancy ablation. Prior studies intimate that composite constructs with MOFs may rectify certain monotherapy defects, bolstering the antineoplastic efficacy—yet not achieving total tumor eradication. Building on previous scholarly work, the author posits that MOF-constructed nano-platforms, when applied in a multimodal targeted therapeutic regimen—encompassing chemotherapy, photodynamic, and photothermal treatments—might eclipse the efficacy of singular targeted approaches.

Notwithstanding the promising laboratory milestones of MOF-centric diagnostic and therapeutic platforms, the transition to clinical applications is fraught with hurdles. MOF composites' complex synthesis, surface modification, and functionalization processes impede their large-scale production and clinical translation. Residual chemical moieties from synthesis, with potential cytotoxicity, remain a concern.^{173,174} Moreover, despite extensive research documenting low cytotoxicity and favorable biocompatibility of MOF composites, these studies are limited by their brief duration. Given MOFs' limited biodegradability, the implications of prolonged human body residence remain to be elucidated through comprehensive basic or clinical investigations.¹⁷² Furthermore, the simulation of MOF circulation in peripheral blood, typically modulated by pH and temperature, fails to account for the complexity of human blood. Enhancing MOF circulation time and evading immune detection are paramount challenges. Strategies to mitigate these challenges include downsizing MOFs or implementing biomimetic modifications, which may effectively reduce immune system recognition and presentation by neutrophils and macrophages. However, the potential aggregation of MOFs in peripheral blood, which could heighten immunogenicity and compromise tumor-targeting efficacy, must be contemplated. A thorough and systematic exploration of in vivo metabolic pathways and degradation processes of MOFs is imperative. Although some researchers have examined the degradation of individual MOF materials via bioimaging, multiple dosages required for targeted tumor therapy necessitate a granular understanding of MOF metabolism and degradation to schedule disparate administration intervals for various MOF composites-preventing MOF accumulation and subsequent bodily harm.

Confronting these challenges in the MOF domain is an onerous scientific endeavor, encompassing synthesis, characterization, application, and mechanistic studies of MOFs. Innovating simplified synthesis detection techniques and refining related strategies are quintessential for expediting MOF research. In an exemplary study, Zhiling Zheng¹⁷⁵ leveraged machine learning to construct a chemical assistant for MOF synthesis prediction, which has significantly streamlined the synthesis process. The chemical assistant's profound integrative and analytical capabilities hold promise for dissecting the impact of synthesis variables on MOF physicochemical properties, potentially elucidating the nexus between MOF nanomaterials' biosafety, biocompatibility, and synthetic methodologies¹⁷⁶ (Figure 8). At the same time,




Figure 8 ChatGPT Schematic of the chemical assistant workflow, efficiently performing text mining using ChatGPT and ChemPrompt, and using machine learning to summarize the effects of MOF synthesis conditions on MOF crystallization from published research articles. Reprinted with permission from Zheng Z, Zhang O, Borgs C, Chayes JT, Yaghi OM. ChatGPT chemistry assistant for text mining and the prediction of MOF synthesis. *J Am Chem Soc.* 2023;145(32):18048–18062. Copyright 2023 American Chemical Society.¹⁷⁶

using artificial intelligence to predict the synthetic results of MOFs is the result of further cross-integration between computer science, medicine, material science, chemistry, and other different disciplines, and it is also the general trend of continuous development in many fields. As far as medicine is concerned, MOFs not only have a broad application prospect in targeted diagnosis and treatment of tumors but also have a pivotal position and transformation potential in many clinical two disciplines, such as tissue engineering, regenerative medicine, and bone science. For example, researchers such as Kai Huang¹⁶³ synthesized a metal-organic framework material QCSMOF-Van with curcumin as the substrate and vancomycin and quaternary ammonium chitosan. The composite system was encapsulated in a hydrogel formed by methacrylic anhydride-modified gelatin and methacrylic anhydride-modified sodium alginate oxide by free radical polymerization and Schiff base reaction. The nano-composite system can exert good antibacterial and anti-inflammatory activities. By interfering with the polarization of macrophages, macrophages can secrete cytokines such as vascular growth factors. In tumor diagnosis, the current main clinical challenges are partially unclear resolution, poor imaging capability, and high cost. Most studies related to MOFs have demonstrated higher performance than commercialized developers. However, there is a lack of focus on production costs. Finding a low-cost contrast agent with superior performance is an important task for MOF research and could significantly reduce healthcare costs worldwide.

In conclusion, this review synthesizes the burgeoning applications of MOF-based nano-composite materials within oncological diagnostics and therapeutics. Drawing upon the collective insights of myriad investigations, it is evident that intelligent nano-platforms engineered from MOFs—leveraging their exceptional porosity and minimized biotoxicity—markedly surpass conventional methodologies when integrated with targeted modalities such as photothermal therapy, photodynamic therapy, and chemotherapy for malignancies. These platforms demonstrate significant potential in improving diagnostic and treatment paradigms for cancer.

Notwithstanding the substantial challenges that impede clinical translation, the field has witnessed considerable advancements in MOF-based targeted cancer diagnostics and therapies, evolving through rigorous research and innovation. The advent of intelligent technologies, such as ChatGTP within chemical synthesis, presages a transformative era, suggesting that the strategic deployment of such intelligent chemical assistants could expedite MOF synthesis substantially.

The past decades have seen an escalation in the deployment of nanotechnology in biomedicine, signaling a paradigm shift as medical research pivots towards the nanomaterial domain, propelled by interdisciplinary collaboration. This review posits that intelligent MOF targeting platforms are poised to assume a pivotal role in the clinical landscape for cancer diagnostics and therapeutics. Progressing from unimodal MOF applications to dual- or multimodal therapies, intelligent MOF-based diagnostic and treatment strategies are anticipated to emerge as innovative clinical modalities, enhancing the management of malignancies.

Acknowledgment

Thanks for the funding from Key Scientific Research Projects of Institutions of Higher Learning in Henan Province (23A416007), Key Project of Innovation Training for College Students in Henan Province (202313505001), Biomedical Engineering-Brand Speciality of Private Ordinary Higher Education Institutions in Henan Province (201952718).

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Wu J, Lin J, Huang P. Harnessing abiotic organic chemistry in living systems for biomedical applications. *Chem Soc Rev.* 2023;52(12):3973–3990. doi:10.1039/d3cs00280b
2. Yang F, Dong J, Li Z, Wang Z. Metal-Organic Frameworks (MOF)-Assisted sonodynamic therapy in anticancer applications. *ACS nano.* 2023;17(5):4102–4133. doi:10.1021/acsnano.2c10251
3. Wang Z, Wang R, Geng Z, et al. Enzyme hybrid nanoflowers and enzyme@metal-organic frameworks composites: fascinating hybrid nanobiocatalysts. *Crit Rev Biotechnol.* 2023;1–24. doi:10.1080/07388551.2023.2189548
4. Fonseca J, Meng L, Imaz I, Maspoch D. Self-assembly of colloidal metal-organic framework (MOF) particles. *Chem Soc Rev.* 2023;52(7):2528–2543. doi:10.1039/d2cs00858k

5. Yan F, Cheng F, Guo C, et al. Curcumin-regulated constructing of defective zinc-based polymer-metal-organic framework as long-acting antibacterial platform for efficient wound healing. *J Colloid Interface Sci.* **2023**;641:59–69. doi:10.1016/j.jcis.2023.03.050
6. Bialy M, Hasiak M, Łaszcz A. Review on biocompatibility and prospect biomedical applications of novel functional metallic glasses. *J Funct Biomat.* **2022**;13(4):245. doi:10.3390/jfb13040245
7. Liu Q, Li A, Liu S, et al. Cytotoxicity of biodegradable zinc and its alloys: a systematic review. *J Funct Biomat.* **2023**;14(4):206. doi:10.3390/jfb14040206
8. Yuan S, Yu R, Tu Y, Du Y, Feng X, Nie F. An enhanced chemiluminescence hybrids of luminol by sulfonated polyaniline decorated copper-based metal organic frame composite applicable to the measurement of hydrogen peroxide in a wide pH range. *Talanta.* **2023**;254:124183. doi:10.1016/j.talanta.2022.124183
9. Rezaee T, Fazel-Zarandi R, Karimi A, Ensafi AA. Metal-organic frameworks for pharmaceutical and biomedical applications. *J Pharmac Biomed Anal.* **2022**;221:115026. doi:10.1016/j.jpba.2022.115026
10. Imanipoor J, Mohammadi M. Porous aluminum-based metal-organic framework-aminoclay nanocomposite: sustainable synthesis and ultrahigh sorption of cephalosporin antibiotics. *Langmuir.* **2022**;38(18):5900–5914. doi:10.1021/acs.langmuir.2c00557
11. Tian C, Zhu L, Lin F, Boyes SG. Poly(acrylic acid) Bridged gadolinium metal-organic framework-gold nanoparticle composites as contrast agents for computed tomography and magnetic resonance bimodal imaging. *ACS Appl Mater Inter.* **2015**;7(32):17765–17775. doi:10.1021/acsami.5b03998
12. Duan D, Liu H, Xu M, et al. Size-controlled synthesis of drug-loaded zeolitic imidazolate framework in aqueous solution and size effect on their cancer theranostics in vivo. *ACS Appl Mater Inter.* **2018**;10(49):42165–42174. doi:10.1021/acsami.8b17660
13. Hoskins BF, Robson R. Infinite polymeric frameworks consisting of three-dimensionally linked rod-like segments. *J Am Chem Soc.* **1989**;111(15):5962–5964. doi:10.1021/ja00197a079
14. Kim J, Chen B, Reineke TM, et al. Assembly of metal-organic frameworks from large organic and inorganic secondary building units: new examples and simplifying principles for complex structures. *J Am Chem Soc.* **2001**;123(34):8239–8247. doi:10.1021/ja010825o
15. Li Z, Zheng A, Mao Z et al. Silk fibroin-gelatin photo-crosslinked 3D-bioprinted hydrogel with MOF-methylene blue nanoparticles for infected wound healing. *Int J Bioprinting.* **2023**;9(5):773. doi:10.18063/ijb.773
16. Chong MWS, Parrott AJ, Ashworth DJ, Fletcher AJ, Nordon A. Non-invasive monitoring of the growth of metal-organic frameworks (MOFs) via Raman spectroscopy. *Phys Chem Chem Phys.* **2023**;25(21):14869–14878. doi:10.1039/d3cp01004j
17. Cai M, Liang W, Wang K et al. Aperture modulation of isoreticular metal organic frameworks for targeted antitumor drug delivery. *ACS Appl Mater Inter.* **2022**;14(32):36366–36378. doi:10.1021/acsami.2c07450
18. Wang J, Zhang Y, Su Y, et al. Fine pore engineering in a series of isoreticular metal-organic frameworks for efficient C₂H₂/CO₂ separation. *Nat Commun.* **2022**;13(1):200. doi:10.1038/s41467-021-27929-7
19. Xin C, Wang W, Xu M, Yu X, Li M, Li S. Construction of Au and C₆₀ quantum dots modified materials of Institute Lavoisier-125(Ti) architectures for antibiotic degradation: performance, toxicity assessment, and mechanistic insight. *J Colloid Interface Sci.* **2022**;623:417–431. doi:10.1016/j.jcis.2022.05.028
20. Hamideh RA, Akbari B, Fathi P, et al. Biodegradable MRI visible drug eluting stent reinforced by metal organic frameworks. *Adv Healthc Mater.* **2020**;9(14):e2000136. doi:10.1002/adhm.202000136
21. He L, Huang G, Liu H, Sang C, Liu X, Chen T. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. *Sci Adv.* **2020**;6(12):eaay9751. doi:10.1126/sciadv.aay9751
22. Abdelhamid HN. Zeolitic Imidazolate Frameworks (ZIF-8) for biomedical applications: a review. *Curr Med Chem.* **2021**;28(34):7023–7075. doi:10.2174/0929867328666210608143703
23. Lei M, Ge F, Zheng H. Stable Cd metal-organic framework as a multiresponsive luminescent biosensor for rapid, accurate, and recyclable detection of hippuric acid, nucleoside phosphates, and Fe³⁺ in urine and serum. *Inorganic Chemistry.* **2022**;61(29):11243–11251. doi:10.1021/acs.inorgchem.2c01313
24. Das M, Jaswal V, Bhambri H et al. Two pillared-layer metal-organic frameworks based on the pinwheel trinuclear carboxylate-clusters of Zn(II) and Co(II): synthesis, crystal structures, magnetic study, and Lewis acid catalysis. *Dalton Trans.* **2003**;52(5):1449–1460. doi:10.1039/d2dt04106e
25. Kim M, Xin R, Earnshaw J et al. MOF-derived nanoporous carbons with diverse tunable nanoarchitectures. *Nat protoc.* **2022**;17(12):2990–3027. doi:10.1038/s41596-022-00718-2
26. Li J, Peng H, Ji W et al. Advances in surface-modified nanometal-organic frameworks for drug delivery. *Int J Pharm.* **2023**;642:123119. doi:10.1016/j.ijpharm.2023.123119
27. Papas D, Ou JY, Plum E, Zheludev NI. Microwatt Volatile Optical Bistability via Nanomechanical Nonlinearity. *Adv. Sci.* **2023**;10(18):e2300042. doi:10.1002/advs.202300042
28. Chai H, Yu K, Zhao Y, et al. MOF-On-MOF dual enzyme-mimic nanozyme with enhanced cascade catalysis for colorimetric/chemiluminescent dual-mode aptasensing. *Anal. Chem.* **2023**;95(28):10785–10794. doi:10.1021/acs.analchem.3c01905
29. Liu Y, Wang Y, Zhao S, Tang Z. Metal-organic framework-based nanomaterials for electrocatalytic oxygen evolution. *Small Methods.* **2022**;6(10):e2200773. doi:10.1002/smt.202200773
30. Olorunyomi JF, Geh ST, Caruso RA, Doherty CM. Metal-organic frameworks for chemical sensing devices. *Mater Horizons.* **2021**;8(9):2387–2419. doi:10.1039/d1mh00609f
31. Jing Y, Li J, Zhang X, et al. Catalase-integrated metal-organic framework with synergetic catalytic activity for colorimetric sensing. *Environ Res.* **2022**;207:112147. doi:10.1016/j.envres.2021.112147
32. He X, Guo Y, Zhang J, et al. Why can poorly conductive Bi@UiO-MOF catalyze CO₂ electroreduction? *Chem Commun* **2023**;59(38):5737–5740. doi:10.1039/d3cc00901g
33. Liang N, Ren N, Feng Z, et al. Biomimetic metal-organic frameworks as targeted vehicles to enhance osteogenesis. *Adv Healthc Mater.* **2022**;11(12):e2102821. doi:10.1002/adhm.202102821
34. Singh M, Bacolla A, Chaudhary S, et al. Histone acetyltransferase MOF orchestrates outcomes at the crossroad of oncogenesis, DNA damage response, proliferation, and stem cell development. *Mol Cell Biol.* **2020**;40(18):e00232–20. doi:10.1128/MCB.00232-20

35. Ma Y, Su Z, Zhou L, et al. Biodegradable metal-organic-framework-gated organosilica for tumor-microenvironment-unlocked glutathione-depletion-enhanced synergistic therapy. *Adv Mater*. 2022;34(12):e2107560. doi:10.1002/adma.202107560
36. Zhang W, Zhou Y, Fan Y, et al. Metal-organic-framework-based hydrogen-release platform for multieffective helicobacter pylori targeting therapy and intestinal flora protective capabilities. *Adv Mater*. 2022;34(2):e2105738. doi:10.1002/adma.202105738
37. Zhao Q, Gong Z, Li Z, et al. Target reprogramming lysosomes of cd8+ t cells by a mineralized metal-organic framework for cancer immunotherapy. *Adv Mater*. 2021;33(17):e2100616. doi:10.1002/adma.202100616
38. Yari H, Gali H, Awasthi V. Nanoparticles for targeting of prostate cancer. *Curr. Pharm. Des.* 2020;26(42):5393–5413. doi:10.2174/1381612826666200721001500
39. Atukorale PU, Covarrubias G, Bauer L, Karathanasis E. Vascular targeting of nanoparticles for molecular imaging of diseased endothelium. *Adv Drug Delivery Rev.* 2017;113:141–156. doi:10.1016/j.addr.2016.09.006
40. Friel H. Biopharmaceutical monotargeting versus ‘universal targeting’ of late-onset alzheimer’s disease using mixtures of pleiotropic natural compounds. *J Alzheimer’s Dis Reports*. 2019;3(1):219–232. doi:10.3233/ADR-190127
41. Zeng K, Yang Y, Xu J, et al. Metal-backboned polymers with well-defined lengths. *Angew Chem*. 2023;62(10):e202216060. doi:10.1002/anie.202216060
42. Wang JY, Mei L, Huang ZW, et al. Coordination-adaptive polydentate pseudorotaxane ligand for capturing multiple uranyl species. *Inorganic Chemistry*. 2022;61(7):3058–3071. doi:10.1021/acs.inorgchem.1c03204
43. Paqui MSS, Glitz VA, Durigon DC, et al. Spectroscopical and molecular studies of four manganese(II) PhotoCORMs with bioinspired ligands containing non-coordinated phenol groups. *Molecules*. 2023;28(8):3439. doi:10.3390/molecules28083439
44. Fang J, Dai L, Feng R, et al. High-performance electrochemiluminescence of a coordination-driven J-Aggregate K-PTC MOF regulated by metal-phenolic nanoparticles for biomarker analysis. *Anal. Chem*. 2023;95(2):1287–1293. doi:10.1021/acs.analchem.2c04159
45. Tili M, Acevedo H, Descoteaux A, Germain M, Heinonen KM. Cell-intrinsic Wnt4 ligand regulates mitochondrial oxidative phosphorylation in macrophages. *J Biol Chem*. 2022;298(8):102193. doi:10.1016/j.jbc.2022.102193
46. Ondrušová S, Kloda M, Rohlíček J, Taddei M, Zaręba JK, Demel J. Exploring the isorecticular continuum between phosphonate- and phosphinate-based metal-organic frameworks. *Inorganic Chemistry*. 2022;61(47):18990–18997. doi:10.1021/acs.inorgchem.2c03271
47. Cao Y, Fu M, Fan S, Gao C, Ma Z, Hou D. Hydrophobic MOF/PDMS-Based QCM Sensors for VOCs Identification and Quantitative Detection in High-Humidity Environments. *ACS Appl Mater Interfaces*. 2024;16(6):7721–7731. doi:10.1021/acsami.3c16228
48. Pardo A, Gómez-Florit M, Barbosa S, Taboada P, Domingues RMA, Gomes ME. Magnetic Nanocomposite Hydrogels for Tissue Engineering: Design Concepts and Remote Actuation Strategies to Control Cell Fate. *ACS Nano*. 2021;15(1):175–209. doi:10.1021/acs.nano.0c08253
49. Andrés MA, Vijjapu MT, Surya SG, et al. Methanol and Humidity Capacitive Sensors Based on Thin Films of MOF Nanoparticles. *ACS Appl Mater Interfaces*. 2020;12(3):4155–4162. doi:10.1021/acs.nano.0c08253
50. Wang JW, Chen GF, Luo GF, et al. A Self-Driven Bioreactor Based on Bacterium-Metal-Organic Framework Biohybrids for Boosting Chemotherapy via Cyclic Lactate Catabolism. *ACS Nano*. 2021;15(11):17870–17884. doi:10.1021/acs.nano.1c06123
51. Gong T, Li Y, Lv B, et al. Full-Process Radiosensitization Based on Nanoscale Metal-Organic Frameworks. *ACS Nano*. 2020;14(3):3032–3040. doi:10.1021/acs.nano.9b07898
52. Dong J, Pan Y, Yang K, et al. Enhanced Biological Imaging via Aggregation-Induced Emission Active Porous Organic Cages. *ACS Nano*. 2022;16(2):2355–2368. doi:10.1021/acs.nano.1c08605
53. Wang P, Li X, Zhang P, et al. Transitional MOFs: Exposing Metal Sites with Porosity for Enhancing Catalytic Reaction Performance. *ACS Appl Mater Interfaces*. 2020;12(21):23968–23975. doi:10.1021/acsami.0c04606
54. Li R, Chen T, Pan X. Metal–Organic–Framework–Based Materials for Antimicrobial Applications. *ACS Nano*. 2021;15(3):3808–3848. doi:10.1021/acs.nano.0c09617
55. Baslan T, Morris JP, Zhao Z, et al. Ordered and deterministic cancer genome evolution after p53 loss. *Nature*. 2022;608(7924):795–802. doi:10.1038/s41586-022-05082-5
56. Lin Y, Peng L, Dong L, et al. Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma. *Cancer Discovery*. 2022;12(10):2350–2371. doi:10.1158/2159-8290.CD-21-1640
57. Liu Z, Zou H, Dang Q, et al. Biological and pharmacological roles of m6A modifications in cancer drug resistance. *Mol Cancer*. 2022;21(1):220. doi:10.1186/s12943-022-01680-z
58. Kolarikova M, Hosikova B, Dilenko H, et al. Photodynamic therapy: innovative approaches for antibacterial and anticancer treatments. *Med Res Rev*. 2023;43(4):717–774. doi:10.1002/med.21935
59. Kim MA, Shin SR, Kim HJ, Lee JS, Lee CM. Chemo-photothermal therapeutic effect of chitosan-gelatin hydrogels containing methotrexate and melanin on a collagen-induced arthritis mouse model. *Int J Biol Macromol*. 2022;218:1013–1020. doi:10.1016/j.ijbiomac.2022.07.227
60. Catanzaro E, Feron O, Skirtach AG, Krysko DV. Immunogenic cell death and role of nanomaterials serving as therapeutic vaccine for personalized cancer immunotherapy. *Front Immunol*. 2022;13:925290. doi:10.3389/fimmu.2022.925290
61. Yang J, Ma S, Xu R, et al. Smart biomimetic metal organic frameworks based on ROS-ferroptosis-glycolysis regulation for enhanced tumor chemo-immunotherapy. *J Control Release*. 2021;334:21–33. doi:10.1016/j.jconrel.2021.04.013
62. Zhang X, Lu Y, Jia D, et al. Acidic microenvironment responsive polymeric MOF-based nanoparticles induce immunogenic cell death for combined cancer therapy. *J Nanobiotechnol*. 2021;19(1):455. doi:10.1186/s12951-021-01217-4
63. Liu P, Hao R, Sun W, Lin Z, Jing T. One-pot synthesis of copper nanocluster/Tb-MOF composites for the ratiometric fluorescence detection of Cu²⁺. *Luminescence*. 2022;37(10):1793–1799. doi:10.1002/bio.4359
64. Li Q, Yu J, Lin L, et al. One-Pot Rapid Synthesis of Cu²⁺-Doped GOD@MOF to amplify the antitumor efficacy of chemodynamic therapy. *ACS Appl Mater Inter*. 2023;15(13):16482–16491. doi:10.1021/acsami.3c00562
65. Li H, Xu C, Li N, et al. Synthesis of bimetallic FeCu-MOF and Its Performance as Catalyst of Peroxymonosulfate for Degradation of Methylene Blue. *Materials*. 2022;15(20):7252. doi:10.3390/ma15207252
66. Li HL, Eddaoudi MM, O’Keeffe M, Yaghi OM. Design and synthesis of an exceptionally stable and highly porous metal-organic framework. *Nature*. 1999;402:276–279.

67. Khaloo SS, Bagheri A, Gholamnia R, Saeedi R. Graphene oxide/MIL 101(Cr) (GO/MOF) nano-composite for adsorptive removal of 2,4-dichlorophenoxyacetic acid (2,4 D) from aqueous media: synthesis, characterization, kinetic and isotherm studies. *Wat Sci Technol*. 2022;86(6):1496–1509. doi:10.2166/wst.2022.282
68. Sun Z, Peng Y, Wang M, et al. Electrochemical deposition of Cu metal-organic framework films for the dual analysis of pathogens. *Anal Chem*. 2021;93(25):8994–9001. doi:10.1021/acs.analchem.1c01763
69. Ameloot R, Stappers L, Franssaer J, Alaerts L, Sels BF, De Vos DE. Patterned growth of metal-organic framework coatings by electrochemical synthesis. *Chem Mater*. 2009;21:2580–2582.
70. Xie S, Zhou Z, Zhang X, Franssaer J. Cathodic deposition of MOF films: mechanism and applications. *Chem Soc Rev*. 2023;52(13):4292–4312. doi:10.1039/d3cs00131h
71. Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. *Cancer Immunol Res*. 2020;8(1):108–119. doi:10.1158/2326-6066.CIR-19-0476
72. Yu B, Choi B, Li W, Kim D. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-020-17380-5
73. Fang H, Li M, Liu Q, et al. Ultra-sensitive nanoprobe modified with tumor cell membrane for UCL/MRI/PET multimodality precise imaging of triple-negative breast cancer. *Nano-Micro Lett*. 2020;12(1). doi:10.1007/s40820-020-0396-4
74. Schilham M, Zamecnik P, Privé B, et al. Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10-enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients. *J Nucl Med*. 2021;62(9):1258–1263. doi:10.2967/jnumed.120.258541
75. Xia L, Meng X, Wen L, et al. A highly specific multiple enhancement theranostic nanoprobe for PET/MRI/PAI image-guided radioisotope combined photothermal therapy in prostate cancer. *Small*. 2021;17(21). doi:10.1002/smll.202100378
76. Rao Y, Xu G, Zhang Z, et al. Coupling doping and localized surface plasmon resonance toward acidic pH-preferential catalase-like nanozyme for oxygen-dominated synergistic cancer therapy. *Chem Eng J*. 2023;465. doi:10.1016/j.cej.2023.142961
77. Aslebagh R, Whitham D, Channaveerappa D, et al. Proteomics analysis of human breast milk by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass spectrometry to assess breast cancer risk. *Electrophoresis*. 2023;44(13–14):1097–1113. doi:10.1002/elps.202300040
78. Wei Z, Yu Y, Hu S, Yi X, Wang J. Bifunctional diblock DNA-mediated synthesis of nanoflower-shaped photothermal nanozymes for a highly sensitive colorimetric assay of cancer cells. *ACS Appl Mater Inter*. 2021;13(14):16801–16811. doi:10.1021/acsami.0c21109
79. Huang R, He L, Li S, et al. A simple fluorescence aptasensor for gastric cancer exosome detection based on branched rolling circle amplification. *Nanoscale*. 2020;12(4):2445–2451. doi:10.1039/c9nr08747h
80. Liao N, Zhong X, Liang W, Yuan R, Zhuo Y. Metal-organic Frameworks (MOF)-based novel electrochemiluminescence biosensing platform for quantification of H₂O₂ releasing from tumor cells. *Acta Chim Sinica*. 2021;79(10):1257–1264. doi:10.6023/A21050223
81. Deng K, Hou Z, Li X, et al. Aptamer-mediated up-conversion Core/MOF shell nanocomposites for targeted drug delivery and cell imaging. *Sci Rep*. 2015;5. doi:10.1038/srep07851
82. Verry C, Dufort S, Lemasson B, et al. Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. *Sci Adv*. 2020;6(29). doi:10.1126/sciadv.aay5279
83. Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF, Leach MO. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. *Radiother Oncol*. 1997;42(1):1–15. doi:10.1016/S0167-8140(96)01866-X
84. Alzola-Aldamizetxebarria S, Fernández-Méndez L, Padro D, Ruiz-Cabello J, Ramos-Cabrer P. A comprehensive introduction to magnetic resonance imaging relaxometry and contrast agents. *ACS omega*. 2022;7(42):36905–36917. doi:10.1021/acsomega.2c03549
85. Rieter W, Taylor K, An H, Lin W, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. *J Am Chem Soc*. 2006;128(28):9024–9025. doi:10.1021/ja0627444
86. Wang Y, Liu W, Yin X. Self-limiting growth nanoscale coordination polymers for fluorescence and magnetic resonance dual-modality imaging. *Adv Funct Mater*. 2016;26(46):8463–8470. doi:10.1002/adfm.201602925
87. Taylor K, Rieter W, Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. *J Am Chem Soc*. 2008;130(44):14358–+. doi:10.1021/ja803777x
88. Zhao D, Zhang W, Yu S, Xia S, Liu Y, Yang G. Application of MOF-based nanotherapeutics in light-mediated cancer diagnosis and therapy. *J Nanobiotechnol*. 2022;20(1). doi:10.1186/s12951-022-01631-2
89. Jiang Q, Xu H, Zhang W, Wang Y, Xia J, Chen Z. Mn(II)-hemoporphyrin-based metal-organic frameworks as a theranostic nanoplatform for MRI-guided sonodynamic therapy. *Biomater Sci*. 2023. doi:10.1039/d3bm01316b
90. Zhang L, Shi X, Zhang Z, et al. Porphyrinic Zirconium Metal-Organic Frameworks (MOFs) as Heterogeneous Photocatalysts for PET-RAFT polymerization and stereolithography. *Angew Chem-Int Ed*. 2021;60(10):5489–5496. doi:10.1002/anie.202014208
91. Idée JM, Pinès E, Prigent P, Corot C. Allergy-like reactions to iodinated contrast agents. A critical analysis. *Fundament Clin Pharmacol*. 2005;19(3):263–281. doi:10.1111/j.1472-8206.2005.00326.x
92. McCollough C, Leng S, Yu L, Fletcher J. Dual- and Multi-Energy CT: principles, technical approaches, and clinical applications. *Radiology*. 2015;276(3):637–653. doi:10.1148/radiol.2015142631
93. deKrafft K, Boyle W, Burk L, Zhou O, Lin W. Zr- and Hf-based nanoscale metal-organic frameworks as contrast agents for computed tomography. *J Mater Chem*. 2012;22(35):18139–18144. doi:10.1039/c2jm32299d
94. Zhang T, Wang L, Ma C, et al. BODIPY-containing nanoscale metal-organic frameworks as contrast agents for computed tomography. *J Mater Chem B*. 2017;5(12):2330–2336. doi:10.1039/c7tb00392g
95. Robison L, Zhang L, Drout RJ, et al. A bismuth metal-organic framework as a contrast agent for X-ray computed tomography. *ACS Appl Bio Mater*. 2019;2(3):1197–1203. doi:10.1021/acsabm.8b00778
96. Wahl R, Jacene H, Kasamon Y, Lodge M. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009;50:122S–150S. doi:10.2967/jnumed.108.057307
97. Chen D, Yang D, Lu W, Hong H. An intrinsically radioactive metal-organic frameworks (MOF) nanomaterial as tumor-targeted, PET-guidable cargo delivery nanoplatform. *J Nucl Med*. 2017;58:2.

98. Zackrisson S, van de Ven S, Gambhir S. Light in and sound out: emerging translational strategies for photoacoustic imaging. *Cancer Res.* **2014**;74(4):979–1004. doi:10.1158/0008-5472.CAN-13-2387
99. Zhang Y, Wang L, Liu L, et al. Engineering metal-organic frameworks for photoacoustic imaging-guided chemo-/photothermal combinational tumor therapy. *ACS Appl Mater Inter.* **2018**;10(48):41035–41045. doi:10.1021/acsami.8b13492
100. Zhang D, Xu H, Zhang X, et al. Self-quenched metal-organic particles as dual-mode therapeutic agents for photoacoustic imaging-guided second near-infrared window photochemotherapy. *ACS Appl Mater Inter.* **2018**;10(30):25203–25212. doi:10.1021/acsami.8b08419
101. Zhou G, Wang YS, Jin Z, et al. Porphyrin-palladium hydride MOF nanoparticles for tumor-targeting photoacoustic imaging-guided hydro-thermothermal cancer therapy. *Nanoscale Horiz.* **2019**;4(5):1185–1193. doi:10.1039/c9nh00021f
102. Li H, Huang M, Wei Z, et al. Hydrogen sulfide activatable metal-organic frameworks for Fluorescence Imaging-Guided Photodynamic Therapy of colorectal cancer. *Front Bioeng Biotechnol.* **2022**;10:1032571. doi:10.3389/fbioe.2022.1032571
103. Padmanabhan P, Kumar A, Kumar S, Chaudhary RK, Gulyás B. Nanoparticles in practice for molecular-imaging applications: an overview. *Acta Biomater.* **2016**;41:1–16. doi:10.1016/j.actbio.2016.06.003
104. Li C, Ye J, Yang X, et al. Fe/Mn Bimetal-Doped ZIF-8-coated luminescent nanoparticles with up/downconversion dual-mode emission for tumor self-enhanced NIR-II imaging and catalytic therapy. *ACS nano.* **2022**;16(11):18143–18156. doi:10.1021/acsnano.2c05152
105. Chen Z, Xie Y, Li Z, Lin T. Dinuclear lanthanide compound as a promising luminescent probe for Al³⁺ Ions. *Molecules.* **2022**;27(24):8761. doi:10.3390/molecules27248761
106. Wuttke S, Braig S, Preiß T, et al. MOF nanoparticles coated by lipid bilayers and their uptake by cancer cells. *Chem Commun.* **2015**;51(87):15752–15755. doi:10.1039/c5cc06767g
107. Chen H, Wang J, Shan D, Chen J, Zhang S, Lu X. Dual-emitting fluorescent metal-organic framework nanocomposites as a broad-range pH sensor for fluorescence imaging. *Anal. Chem.* **2018**;90(11):7056–7063. doi:10.1021/acs.analchem.8b01455
108. Gao J-L, Liu Y-H, Zheng B, et al. Light-activated and self-driven autonomous DNA nanomachine enabling fluorescence imaging of MicroRNA in living cells with exceptional precision and efficiency. *ACS Appl Mater Inter.* **2021**;13(27):31485–31494. doi:10.1021/acsami.1c07333
109. Zhao L, Zhang W, Wu Q, et al. Lanthanide europium MOF nanocomposite as the theranostic nanoplatform for microwave thermo-chemotherapy and fluorescence imaging. *J Nanobiotechnol.* **2022**;20(1):133. doi:10.1186/s12951-022-01335-7
110. Tang T, Yuan R, Guo N, et al. Improving the surface area of metal organic framework-derived porous carbon through constructing inner support by compatible graphene quantum dots. *J Colloid Interface Sci.* **2022**;623:77–85. doi:10.1016/j.jcis.2022.04.161
111. Sun M, Zhang L, Xu S, et al. Carbon dots-decorated hydroxyapatite nanowires-lanthanide metal-organic framework composites as fluorescent sensors for the detection of dopamine. *Analyst.* **2022**;147(5):947–955. doi:10.1039/d2an00049k
112. Zhang H, Shang Y, Li Y, Sun S, Yin X. Smart metal-organic framework-based nanoplatfroms for imaging-guided precise chemotherapy. *ACS Appl Mater Inter.* **2019**;11(2):1886–1895. doi:10.1021/acsami.8b19048
113. Ma Y, Mao J, Qin H, et al. Nano-metal-organic framework decorated with PT nanoparticles as an efficient theranostic nanoprobe for CT/MRI/PAI imaging-guided radio-photothermal synergistic cancer therapy. *Front Bioengin Biotechnol.* **2022**;10. doi:10.3389/fbioe.2022.927461
114. Li Y, Tang J, He L. Core-shell upconversion Nanoparticle@metal-organic framework nanoprobe for luminescent/magnetic dual-mode targeted imaging. *Adv Mater.* **2015**;27(27):4075–4080. doi:10.1002/adma.201501779
115. Wang D, Zhou J, Chen R, et al. Controllable synthesis of dual-MOFs nanostructures for pH-responsive artemisinin delivery, magnetic resonance and optical dual-model imaging-guided chemo/photothermal combinational cancer therapy. *Biomaterials.* **2016**;100:27–40. doi:10.1016/j.biomaterials.2016.05.027
116. Cai W, Gao H, Chu C, et al. Engineering phototheranostic nanoscale metal-organic frameworks for multimodal imaging-guided cancer therapy. *ACS Appl Mater Inter.* **2017**;9(3):2040–2051. doi:10.1021/acsami.6b11579
117. Gao H, Ji Q, Chi B, et al. Achieving a “all in one” Fe/Tm-MOFs with controllable photothermal and catalytic performance for imaging-guided multi-modal synergetic therapy. *J Coll Inter Sci.* **2022**;623:124–134. doi:10.1016/j.jcis.2022.05.015
118. Maomao C, He L, Dianqin S, et al. Current cancer burden in China: epidemiology, etiology, and prevention. *Canc Biol Med.* **2022**;19(8):1121–1138. doi:10.20892/j.issn.2095-3941.2022.0231
119. Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J. From patterns to patients: advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. *Cell.* **2023**;186(8):1772–1791. doi:10.1016/j.cell.2023.01.035
120. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. *Indian J Med Res.* **2022**;156(4&5):598–607. doi:10.4103/ijmr.ijmr_1821_22
121. Yun B, Gu Z, Liu Z, Han Y, Sun Q, Li Z. Reducing Chemo-/Radioresistance to Boost the Therapeutic Efficacy against Temozolomide-Resistant Glioblastoma. *ACS Appl Mater Inter.* **2022**;14(34):38617–38630. doi:10.1021/acsami.2c12348
122. Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. *World J Gastroenterol.* **2021**;27(20):2434–2457. doi:10.3748/wjg.v27.i20.2434
123. Karschnia P, Young JS, Dono A, et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. *Neuro-Oncology.* **2023**;25(5):940–954. doi:10.1093/neuonc/noac193
124. Ippolito MR, Martis V, Martin S, et al. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. *Dev. Cell.* **2021**;56(17):2440–2454.e6. doi:10.1016/j.devcel.2021.07.006
125. Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer. *Cancer Discovery.* **2022**;12(11):2586–2605. doi:10.1158/2159-8290.CD-22-0200
126. Li F, Zheng Z, Chen W, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. *Drug Resist Updates.* **2023**;68:100938. doi:10.1016/j.drug.2023.100938
127. Francolini G, Desideri I, Stocchi G, et al. Artificial Intelligence in radiotherapy: state of the art and future directions. *Med Oncol.* **2020**;37(6):50. doi:10.1007/s12032-020-01374-w
128. Cinicola J, Mamidanna S, Yegya-Raman N, Spencer K, Deek MP, Jabbour SK. A review of advances in radiotherapy in the setting of esophageal cancers. *Surg Oncol Clin North Am.* **2023**;32(3):433–459. doi:10.1016/j.soc.2023.03.004
129. Jia C, Guo Y, Wu FG. Chemodynamic therapy via fenton and fenton-like nanomaterials: strategies and recent advances. *Small.* **2022**;18(6):e2103868. doi:10.1002/sml.202103868

130. Gustalik J, Aebisher D, Bartusik-Aebisher D. Photodynamic therapy in breast cancer treatment. *J Appl Biomed*. 2022;20(3):98–105. doi:10.32725/jab.2022.013
131. Ke CH, Chiu YH, Huang KC, Lin CS. Exposure of immunogenic tumor antigens in surrendered immunity and the significance of autologous tumor cell-based vaccination in precision medicine. *Int J Mol Sci*. 2022;24(1):147. doi:10.3390/ijms24010147
132. Deng H, Zhang J, Yang Y, et al. Chemodynamic and photothermal combination therapy based on dual-modified metal-organic framework for inducing tumor ferroptosis/pyroptosis. *ACS Appl Mater Inter*. 2022;14(21):24089–24101. doi:10.1021/acsami.2c00574
133. Ren X, Yuan W, Ma J, et al. Magnetic nanocluster-mediated photothermal effect and macrophage modulation for synergistic photothermal immunotherapy of cancer. *Biomater Sci*. 2022;10(12):3188–3200. doi:10.1039/d1bm01770e
134. Xue J, Zhu Y, Bai S, et al. Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma. *Acta pharmaceutica Sinica B*. 2022;12(6):2934–2949. doi:10.1016/j.apsb.2021.11.020
135. Wang Z, Wang M, Wang X, et al. Photothermal-based nanomaterials and photothermal-sensing: an overview. *Biosens Bioelectron*. 2023;220:114883. doi:10.1016/j.bios.2022.114883
136. Sun XY, Zhang HJ, Zhao XY, Sun Q, Wang YY, Gao EQ. Dual functions of pH-sensitive cation Zr-MOF for 5-Fu: large drug-loading capacity and high-sensitivity fluorescence detection. *Dalton Trans*. 2003;50(30):10524–10532. doi:10.1039/d1dt01772a
137. Liang J, Zhang W, Wang J, et al. Development of the Cu/ZIF-8 MOF acid-sensitive nanocatalytic platform capable of chemo/chemodynamic therapy with improved anti-tumor efficacy. *ACS omega*. 2023;8(22):19402–19412. doi:10.1021/acsomega.3c00269
138. Chen Z, Sun Y, Wang J, et al. Dual-responsive triple-synergistic Fe-MOF for tumor theranostics. *ACS nano*. 2023;17(10):9003–9013. doi:10.1021/acsnano.2c10310
139. Taheri-Ledari R, Zarei-Shokat S, Qazi FS, et al. A mesoporous magnetic Fe₃O₄/BioMOF-13 with a core/shell nanostructure for targeted delivery of doxorubicin to breast cancer cells. *ACS Appl Mater Inter*. 2023. doi:10.1021/acsami.3c14363
140. Javanbakht S, Hemmati A, Namazi H, Heydari A. Carboxymethylcellulose-coated 5-fluorouracil@MOF-5 nano-hybrid as a bio-nanocomposite carrier for the anticancer oral delivery. *Int J Biol Macromol*. 2020;155:876–882. doi:10.1016/j.ijbiomac.2019.12.007
141. Li RT, Zhu YD, Li WY, et al. Synergistic photothermal-photodynamic-chemotherapy toward breast cancer based on a liposome-coated core-shell AuNS@NMOFs nanocomposite encapsulated with gambogic acid. *J Nanobiotechnol*. 2022;20(1):212. doi:10.1186/s12951-022-01427-4
142. Egloff-Juras C, Bezdetnaya L, Dolivet G, Lassalle HP. NIR fluorescence-guided tumor surgery: new strategies for the use of indocyanine green. *Int J Nanomed*. 2019;14:7823–7838. doi:10.2147/IJN.S207486
143. O'Toole MG, Soucy PA, Chauhan R, et al. Release-modulated antioxidant activity of a composite curcumin-chitosan polymer. *Biomacromolecules*. 2016;17(4):1253–1260. doi:10.1021/acs.biomac.5b01019
144. Zou H, Li M, Li X, et al. Multimodal imaging and photothermal synergistic immunotherapy of retinoblastoma with tuftsin-loaded carbonized MOF nanoparticles. *Drug Delivery*. 2022;29(1):1785–1799. doi:10.1080/10717544.2022.2081379
145. Yang Y, Liu J, Liang C, et al. Nanoscale metal-organic particles with rapid clearance for magnetic resonance imaging-guided photothermal therapy. *ACS nano*. 2016;10(2):2774–2781. doi:10.1021/acsnano.5b07882
146. Zhu YD, Chen SP, Zhao H, et al. PPy@MIL-100 nanoparticles as a pH- and Near-IR-irradiation-responsive drug carrier for simultaneous photothermal therapy and chemotherapy of cancer cells. *ACS Appl Mater Inter*. 2016;8(50):34209–34217. doi:10.1021/acsami.6b11378
147. Wei G, Wang Y, Yang G, Wang Y, Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. *Theranostics*. 2021;11(13):6370–6392. doi:10.7150/thno.57828
148. Liu X, He Z, Chen Y, et al. Dual drug delivery system of photothermal-sensitive carboxymethyl chitosan nanosphere for photothermal-chemotherapy. *Int J Biol Macromol*. 2020;163:156–166. doi:10.1016/j.ijbiomac.2020.06.202
149. Chung S, Revia RA, Zhang M. Graphene quantum dots and their applications in bioimaging, biosensing, and therapy. *Adv Mater*. 2021;33(22):e1904362. doi:10.1002/adma.201904362
150. Gelişken F. Indocyanine Green Angiography. *Turk J Ophthalmol*. 2024;54(1):38–45. doi:10.4274/tjo.galenos.2023.89735
151. Hao Y, Liu T, Zhou H, Peng J, Li K, Chen Y. The GSH responsive indocyanine green loaded PD-1 inhibitory polypeptide AUNP12 modified MOF nanoparticles for photothermal and immunotherapy of melanoma. *Front Bioeng Biotechnol*. 2023;11:1294074. doi:10.3389/fbioe.2023.1294074
152. Lu K, He C, Lin W. Nanoscale metal-organic framework for highly effective photodynamic therapy of resistant head and neck cancer. *J Am Chem Soc*. 2014;136(48):16712–16715. doi:10.1021/ja508679h
153. Wang X, Wang Z, Ma W, et al. Construction of a nanotheranostic system Zr-MOF@PPa/AF@PEG for improved photodynamic therapy effects based on the PDT-oxygen consumption and hypoxia sensitive chemotherapeutic drug. *J Photochem Photobiol B Biol*. 2021;222:112274. doi:10.1016/j.jphotobiol.2021.112274
154. Lu J, Yang L, Zhang W, et al. Photodynamic therapy for hypoxic solid tumors via Mn-MOF as a photosensitizer. *Chem. Commun*. 2019;55(72):10792–10795. doi:10.1039/c9cc05107d
155. Liang Z, Li X, Chen X, et al. Fe/MOF based platform for NIR laser induced efficient PDT/PTT of cancer. *Front Bioeng Biotechnol*. 2023;11:1156079. doi:10.3389/fbioe.2023.1156079
156. Park J, Jiang Q, Feng D, Mao L, Zhou HC. Size-controlled synthesis of porphyrinic metal-organic framework and functionalization for targeted photodynamic therapy. *J Am Chem Soc*. 2016;138(10):3518–3525. doi:10.1021/jacs.6b00007
157. Zhuang J, Gong H, Zhou J, et al. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles. *Sci Adv*. 2020;6(13):eaaz6108. doi:10.1126/sciadv.aaz6108
158. Huang R, Cai GQ, Li J, et al. Platelet membrane-camouflaged silver metal-organic framework drug system against infections caused by methicillin-resistant *Staphylococcus aureus*. *J Nanobiotechnol*. 2021;19(1):229. doi:10.1186/s12951-021-00978-2
159. Zhang Y, Zhu H, Ying Z, et al. Design and application of metal organic framework ZIF-90-ZnO-MoS₂ nanohybrid for an integrated electrochemical liquid biopsy. *Nano Lett*. 2022;22(16):6833–6840. doi:10.1021/acs.nanolett.2c01613
160. Zhang L, Gao Y, Sun S, Li Z, Wu A, Zeng L. pH-Responsive metal-organic framework encapsulated gold nanoclusters with modulated release to enhance photodynamic therapy/chemotherapy in breast cancer. *J Mater Chem*. 2020;8(8):1739–1747. doi:10.1039/c9tb02621e
161. Chen Z, Wu Y, Yao Z, et al. 2D Copper(II) metalated metal-organic framework nanocomplexes for dual-enhanced photodynamic therapy and amplified antitumor immunity. *ACS Appl Mater Inter*. 2022;14(39):44199–44210. doi:10.1021/acsami.2c12990

162. Huang X, Lu Y, Guo M, Du S, Han N. Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view. *Theranostics*. 2021;11(15):7546–7569. doi:10.7150/thno.56482
163. Song J, Sun X, Du Y, et al. Micro-opening ridged waveguide tumor hyperthermia antenna combined with microwave-sensitive MOF material for tumor microwave hyperthermia therapy. *ACS Appl. Bio Mater.* 2022. doi:10.1021/acsabm.2c00234
164. Xu R, Yang J, Qian Y, et al. Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF. *Nanoscale Horiz.* 2021;6(4):348–356. doi:10.1039/d0nh00674b
165. Giliopoulos D, Zamboulis A, Giannakoudakis D, Bikiaris D, Triantafyllidis K. Polymer/Metal Organic Framework (MOF) nanocomposites for biomedical applications. *Molecules*. 2020;25(1):185. doi:10.3390/molecules25010185
166. Yang S, Peng L, Bulut S, Queen WL. Recent advances of MOFs and MOF-derived materials in thermally driven organic transformations. *Chemistry*. 2019;25(9):2161–2178. doi:10.1002/chem.201803157
167. Cui B, Fu G. Process of metal-organic framework (MOF)/covalent-organic framework (COF) hybrids-based derivatives and their applications on energy transfer and storage. *Nanoscale*. 2022;14(5):1679–1699. doi:10.1039/d1nr07614k
168. Zhang X, Yang Y, Li D, et al. MOF negatively regulates estrogen receptor α signaling via CUL4B-mediated protein degradation in breast cancer. *Front Oncol.* 2022;12:868866. doi:10.3389/fonc.2022.868866
169. Xu K, Zhang S, Zhuang X, et al. Recent progress of MOF-functionalized nanocomposites: from structure to properties. *Adv Colloid Interface Sci.* 2024;323:103050. doi:10.1016/j.cis.2023.103050
170. Qian Y, Zhai E, Chen S, et al. Single-cell RNA-seq dissecting heterogeneity of tumor cells and comprehensive dynamics in tumor microenvironment during lymph nodes metastasis in gastric cancer. *Int J Canc.* 2022;151(8):1367–1381. doi:10.1002/ijc.34172
171. Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. *Protein and Cell.* 2022;13(12):877–919. doi:10.1007/s13238-021-00846-7
172. Yang T, Zhang S, Yuan H, et al. Platinum-Based TREM2 inhibitor suppresses tumors by remodeling the immunosuppressive microenvironment. *Angew Chem.* 2023;62(2):e202213337. doi:10.1002/anie.202213337
173. Abánades Lázaro I, Haddad S, Rodrigo-Muñoz JM, et al. Surface-FUNCTIONALIZATION of Zr-Fumarate MOF for selective cytotoxicity and immune system compatibility in nanoscale drug delivery. *ACS Appl Mater Inter.* 2018;10(37):31146–31157. doi:10.1021/acsami.8b11652
174. Tamames-Tabar C, Cunha D, Imbuluzqueta E, et al. Cytotoxicity of nanoscaled metal-organic frameworks. *J Mater Chem.* 2014;2(3):262–271. doi:10.1039/c3tb20832j
175. Zhou J, Tian G, Zeng L, Song X, Bian XW. Nanoscaled metal-organic frameworks for biosensing, imaging, and cancer therapy. *Adv Healthc Mater.* 2018;7(10):e1800022. doi:10.1002/adhm.201800022
176. Zheng Z, Zhang O, Borgs C, Chayes JT, Yaghi OM. ChatGPT chemistry assistant for text mining and the prediction of MOF synthesis. *J Am Chem Soc.* 2023;145(32):18048–18062. doi:10.1021/jacs.3c05819

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>